University of South Carolina

Scholar Commons
Theses and Dissertations
2016

Biodegradable Hybrid Tissue Engineering Scaffolds For
Reconstruction Of Large Bone Defects
Danial Barati
University of South Carolina

Follow this and additional works at: https://scholarcommons.sc.edu/etd
Part of the Chemical Engineering Commons

Recommended Citation
Barati, D.(2016). Biodegradable Hybrid Tissue Engineering Scaffolds For Reconstruction Of Large Bone
Defects. (Doctoral dissertation). Retrieved from https://scholarcommons.sc.edu/etd/3807

This Open Access Dissertation is brought to you by Scholar Commons. It has been accepted for inclusion in
Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please
contact digres@mailbox.sc.edu.

BIODEGRADABLE HYBRID TISSUE ENGINEERING
SCAFFOLDS FOR RECONSTRUCTION OF LARGE BONE
DEFECTS
By

Danial Barati
Bachelor of Chemical Engineering
University of Tehran, 2009
Master of Science
University of South Carolina, 2013
Submitted in Partial Fulfillment of the Requirements
For the Degree of Doctor of Philosophy in
Chemical Engineering
College of Engineering and Computing
University of South Carolina
2016
Accepted by:
Esmaiel Jabbari , Major Professor
Francis Gadala-Maria, Committee Member
John Lavigne, Committee Member
Michael Gower, Committee Member
John W. Weidner, Committee Member
Lacy Ford, Senior Vice Provost and Dean of Graduate Studies

i

© Copyright by Danial Barati, 2016
All Rights Reserved.
ii

DEDICATION
I dedicate my dissertation work to my family and many friends. A special feeling of
gratitude to my loving parents, and specifically my mom whose words of encouragement
and push for tenacity ring in my ears. My sister Elham and my uncle Dr. Behravesh have
never left my side and are very special.

iii

ACKNOWLEDGEMENTS
I would like to be deeply grateful to my adviser, Prof. Esmaiel Jabbari for giving me
the chance of working in his group and supporting me for 6 years to complete my
Master’s and Ph.D. programs in university of South Carolina. Also, I thank all my lab
members (Dr. Moeinzadeh, Dr. He, Dr. Mercado, Dr. Karimi, Dr. Shariati, Safaa, Nazli,
Leily and Samaneh) and undergraduate researchers who help me to complete my
projects. I am strongly thankful to all of my friends in US and specifically Iranian friends
who never left me alone during these years. Most importantly, none of this would have
been possible without the love and patience of my family. My immediate family to whom
this dissertation is dedicated to, has been a constant source of love, concern, support and
strength all these years. I would like to express my heart-felt gratitude to my family. My
extended family has aided and encouraged me throughout this endeavor.

iv

ABSTRACT
Complex skeletal injuries and large bone fractures are still a significant clinical
problem in US. Approximately 1.5 million Americans (veterans, their families, and
civilians) every year suffer from bone loss due to traumatic skeletal injuries, infection,
and resection of primary tumors that require extensive grafting to bridge the gap. The US
bone graft market is over $2.2 billion a year. Due to insufficient mechanical stability,
lack of vascularity, and inadequate resorption of the graft, patients with traumatic large
skeletal injuries undergo multiple costly operations followed by extensive recovery steps
to maintain proper bone alignment and length. Current strategies for repairing damaged
or diseased bones include autologous or allograft bone transplantations. However, limited
availability of autografts and risk of disease transmission associated with allografts have
necessitated the search for the development of new bone graft options and strategies.
The overall goal of this project is to develop a much-needed bone-mimetic
engineered graft as a substitute for current strategies providing required bone grafts for
reconstruction of large bone defects. This project will use the structure of natural cortical
bone as a guide to produce an engineered bone graft with balanced strength, osteogenesis,
vascularization, and resorption. The outcome of this project will be a biodegradable
hybrid scaffold system (similar to natural cortical bone) including a mechanically strong
scaffold allowing for mechanical stability of the load-bearing defect site and a soft and
highly porous structure such as a hydrogel phase which will allow for efficient cell and
v

growth factor delivery into the defect implantation site, cell niche establishment and
promotion of mineralization. Successful completion of this project will transform bone
graft technology for regeneration of complex bone defects from a frozen or freeze-dried
allograft to a safe, infection-free, mechanically-stable, osteoinductive, and vasculogenic
graft that is ultimately displaced by the patient’s own tissue.
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CHAPTER 1: BACKGROUND INFORMATION
1. General introduction
Repair and restoration of damaged bone is a major clinical challenge as well as an
economic burden. Current strategies for repairing damaged or diseased bones include
autologous or allograft bone transplantations. However, limited availability of autografts
and risk of disease transmission associated with allografts have necessitated the search
for the development of new bone graft options and strategies 1. Tissue engineering has
recently emerged as an alternative strategy for bone defect repair and regeneration. In this
strategy, a biodegradable scaffold is often utilized along with osteogenic cells and/or
bone inducing factors to mimic the natural structure of the tissue.

Figure 1.1: Tissue engineering approach for reconstruction of large bone fractures

1

Bone tissue is composed of an external layer, referred to as cortical or compact bone,
and an internal layer, referred to as cancellous or spongy bone 2. Cortical bone makes up
to ~80% of the total bone mass in adults. It is extremely dense, with low porosity (20%)
and high mechanical strength (130-190 MPa). Cancellous (spongy) bone accounts for the
other 20% of the total bone mass and is highly porous (50%–90%), to allow for better
penetration of vasculature, with ~10% of the mechanical strength of cortical bone 3.
Although cortical and cancellous layers are quite different in structure, they both contain
a highly vascularized network. The presence of a vascular network is essential to supply
nutrients and remove waste products. The main source of blood cells and vascular
structures in bone is bone marrow 4. Bone marrow is a soft, gelatinous and highly
vascularized connective tissue within bone cavities and the spaces between the trabeculae
of spongy bone. Bone marrow is either red or yellow, depending upon the preponderance
of hematopoietic (red) or fatty (yellow) tissue 5.
A scaffold for bone regeneration should satisfy basic scaffold requirements such as
biocompatibility, interconnected pore structure for tissue in-growth, and controlled
degradation with physiologically-friendly degradation products

6, 7

. In addition, an ideal

bone tissue engineering graft should provide suitable weight-bearing mechanical
properties and have both excellent proosteogenesis and proangiogenesis to rapidly realize
the bone regeneration in vivo 8, 9.

2

Figure 1.2. Bone anatomy (Copyright ª 2004 Pearson Education, Inc., publishing as
Benjamin Cummings).

In fact, the healing of bone defect is a complex, coordinated temporal process
involving a myriad of molecular, cellular, biochemical and mechanical cues, among
which angiogenesis, or neovascularization, is a critical factor for regenerative bone tissue,
because the existence of a functional vascular network within the defect site can provide
sufficient oxygen and nutrients to facilitate growth, differentiation, and tissue
functionality, which is of particular importance for bone regeneration

10

. Thereupon, a

desirable scaffold which could provide high mechanical stability and promote
angiogenesis as well as osteogenesis during the bone regeneration process is worthy of
study.
Although great strides have been made, it is difficult for any biomaterial to satisfy all
of the listed requirements. To develop better scaffolds for bone regeneration, researchers
3

have attempted to integrate mechanically strong and porous scaffolds with soft and
hydrated scaffolds such as hydrogels. These structures are referred to as hybrid scaffolds
11, 12

. In this approach, the mechanically strong scaffold component would allow for

mechanical stability of the load-bearing defect site; whereas, the hydrogel phase will
allow for efficient cell delivery into the defect implantation site, cell niche establishment
and promotion of mineralization. Hydrogels are polymeric, soft and flexible networks
that have the ability to absorb and retain a large volume of water (80%–99%) without
dissolving

13

. Hydrogels can be made from natural biodegradable polymers such

collagen, chitosan, and gelatin, or synthetic polymers such as polyethylene glycol (PEG)
and polyvinyl alcohol

14, 15

. Their remarkable properties, including similarities with the

ECM, proper biological performance, hydrophilicity, high permeability to oxygen and
nutrients, and inherent cellular interaction capabilities, make them leading candidates for
engineered tissue scaffolds 13. Also, growth factors for the promotion of accelerated bone
and vascularization (i.e., BMP, VEGF) may also be covalently tethered to the hydrogel
phase to allow for enhanced effects upon implantation. For instance, non-degradable
hybrid scaffolds were fabricated by loading a self-assembling peptide into a porous
titanium or polyetheretherketone cage to study bone regeneration in vitro and in vivo
12

11,

. The observed bone regeneration was superior to hybrid grafts since the hydrogel phase

offered a native environment for bone forming cells while the porous matrix
mechanically supported bone regeneration

12

. In addition, hybrid grafts offer the

possibility of osteogenic cell and factor encapsulation. The newly developed “polymerhydrogel” hybrid system is robust: it not only satisfies mechanical needs but also has the
ability to load the cells and factors required for osteogenesis and vasculogenesis
4

16

.

Therefore, there is a clear need to develop biodegradable hybrid scaffold systems for
effective bone tissue engineering.
Shortly, the overall aim of the present study is to develop a biodegradable hybrid
scaffold system (similar to natural cortical bone shown in figure 1.2) that is weight
bearing and osteoinductive for effective bone regeneration (Figure 1.3). We will address
the most critical challenges separately to design an optimized hybrid structure with the
final goal of improving the bone healing process.

Figure 1.3. Engineered cortical bone-mimetic scaffold

The first major challenge in designing scaffolds for reconstruction of large bone
defects is the graft’s mechanical stability and toughness. The engineered graft should be
sufficiently rigid for closure of the skeletal gap to maintain homeostasis

17

. Further, the

engineered graft should be osteo-conductive/inductive and ultimately be replaced by the
natural bone. The second major challenge in reconstruction of large bone defects is
insufficient vascularization. Current tissue engineering strategies are extremely limited by
5

the lack of vascularization, leading to poor graft integration and failure of engineered
substitutes in clinical trials

17

. Since diffusion of nutrients and oxygen to the progenitor

cells in the graft is limited to a few hundred micrometers, successful regeneration of large
bone defects requires early induction of vascularization in the graft 18, 19. It is notable that
the final effective bone regeneration and vessel formation in a critical sized defect are
also attributed to the close association and interaction between angiogenesis and
osteogenesis 20. One hand, most osteogenic factors such as Bone Morphogenetic Protein2 (BMP2) involved in osteogenesis stimulate angiogenesis, if not directly, then indirectly,
through production of angiogenic molecules, such as Vascular Endothelial Growth Factor
(VEGF)

16, 21

. For example, it has been clarified that during endochondral ossification,

there is close correlation between vascularization and bone formation as the maximum
extent of bone formation follows maximum levels of VEGF expression 22. Therefore, the
engineered graft should provide a compliant permissive environment such as a hydrogel
phase which allows for efficient cell delivery into the defect implantation site, cell niche
establishment and promotion of vascularization and osteogenesis

23

. The third challenge

is timed-release of growth factors in their respective microenvironments. Interactions
between cells play an important role in directing their function and differentiation. In
vivo cellular communication is mainly through a cascade of chemical cues, such as
protein interactions and growth factor signaling. Growth factors are known to affect
cellular proliferation, migration, and differentiation during bone repair

24

. Owing to the

critical role of growth factors in controlling basic cellular functions, and their ability to
directly elicit and arrange tissue regeneration, a wide range of growth factors has been
tested for distinct therapeutic applications, including bone regeneration and
6

neovascularization of ischaemic tissues. For instance, bone morphogenetic protein-2
(BMP-2), transforming growth factor-β (TGF-β), fibroblast growth factor (FGF), plateletderived growth factor (PDGF), insulin-like growth factor (IGF), endothelin-1, and
vascular endothelial growth factor (VEGF) are involved in bone formation

25

. BMP,

PDGF, FGF, and VEGF have been shown to enhance migration of osteoprogenitor cells,
while TGF-β, IGFs, and BMPs modulate their proliferation and differentiation

26

.

Additionally, VEGF and FGF are involved in initiating vascular growth during bone
healing

25

. The cross-talk between osteoblasts and endothelial cells (ECs) is conducted

through the release of VEGF by osteoblasts, which act on ECs to promote angiogenesis,
and through the release of BMPs by ECs, which act on precursor bone cells to promote
osteoblastic differentiation. In addition, FGF has been shown to stimulate proliferation
and migration of ECs

27

and also induce osteoblasts differentiation28. Therefore, one

efficient way to obtain osteoinductivity and enhance repair of the critical sized bone
defects is application of growth factors such as of BMP2 and VEGF as it has been largely
reported

29

. However, concerns about these bioactive strategies still remain, such as the

uncontrollable dose and composition of the delivered growth factors, and a high
degradation rate resulting from a high in vivo instability of the angiogenic factors

30

.

Currently, for the clinical therapy, BMP-2 in a high dosage thereafter a high cost need to
be used, which is possibly accompanied by the contingent risk and side effect, such as
excessive bone resorption and promotion of tumor angiogenesis 31, 32. Furthermore, it has
been shown that the extent of bone formation in vivo depends on the duration of exposure
of osteoprogenitor cells and endothelial progenitor cells to BMP2 and VEGF,

7

respectively

33-35

. Therefore, the controlled delivery system of growth factors becomes

increasingly necessary and important.
To address these challenges, the idea is to utilize novel nanomaterials to mimic the
shell-core structure of cortical bone which is composed of interconnected network of
microcanals, and a compliant, permissive core with timed and localized release of BMP2
and VEGF to form an osteoblastic-vascular niche (Figure 1.3). In nano scale, bone has a
nanocomposite structure made of collagen type I nanofibers (~ 30 wt%) and
hydroxyapatite nanocrystals (~ 70 wt%) .

The superior mechanical stability and

osteoinductivity of cortical bone in the natural tissue stem from the presence of high
amount of hydroxylapatite nanocrystals on the surface of collagen nanofibers (Figure
1.4a). Therefore, to address the first challenge, aligned polylactide (PLA) nanofibers with
a tunable degradation time were mineralized with high quantity of calcium phosphate
(CaP) nanocrystals by incubation in simulated body fluid (SBF) supplemented with bonederived organic acids (Ami 1, Figure 1.4b).

Figure 1.4. a) Aim 1: Nanostrucuture of natural cortical bone. b) Engineering approach to
mimic the nanostructure of cortical bone

8

Then, the CaP-nucleated nanofiber microsheets will be wrapped into microtubes and
a set of microtubes will be assembled around a cylindrical mold and allowed to fuse by
annealing above the glass transition temperature (Tg) of PLA nanofibers to form a rigid,
tough, osteoconductive, cylindrical shell.
As it was mentioned earlier, the main source of blood cells and vascular structures in
bone is a soft, gelatinous and highly porous structure called bone marrow which is placed
in the core of cortical bone and empty spaces in cancellous bone. Hence, to address the
second challenge, a compliant hydrogel loaded with required cells and growth factors
will be designed to form a osteoblastic-vascular niche in the structure of the engineered
scaffold.

Figure 1.5. Aim 2 and 3: Compliant hydrogel loaded with required cells and growth factors
to mimic soft structure of bone marrow

It should be also emphasized that osteogenesis and vascularization processes are
coupled during the bone formation and regeneration as maximum extent of osteogenesis
follows maximum level of vascularization and vice-versa. Therefore, in this work, a
patterned hydrogel were designed to facilitate controlling both osteogenesis and
vasculogenesis processes in the scaffold and consequently increase the extent of bone
9

formation. Moreover, to address the third challenge, a set of nanogels (NGs) were
engineered to control the release rate of growth factors in patterned hydrogel. To do this,
polyethylene glycol (PEG) chain-extended with short lactide (L) and glycolide (G)
segments were used to form self-assembled NGs and facilitate a wide range of timedrelease for different types of growth factors such as BMP2 and VEGF.

Accordingly, the following aims are considered to test the hypothesis toward the
objectives.
Aim 1. To engineer a cortical-bone-mimetic nanostructured shell by fabricating
mineralized

nanofibers

and

evaluate

with

respect

to

mechanical

strength.

osteoconductivity, and degradability.
Ami 2. To synthesize resorbable, self-assembled, polyethylene glycol based nanogels and
evaluate with respect to size, degardation rate and the release kinetics of BMP2- and
VEGE-grafted nanogels.
Ami 3. To evaluate the extent of vasculogenesis and osteogenesis of human
mesenchymal stem cells (hMSCs) and human colony-forming endothelial cells (ECFCs)
encapsulated in a patterned hydrogel with spatiotemporal release of BMP2 and VEGF.

10

CHAPTER 2: FABRICATION AND CHARACTERIZATION OF MINERALIZED
NANOFIBERS USING SIMULATED BODY FLUID SUPPLEMENTED WITH
BONE-DERIVED ORGANIC ACID 1
1. Introduction
Reconstruction of large incomplete bone segments remains a significant clinical
problem

36, 37

. Frozen allogeneic bone graft is used but the long-term failure rate of

allografts in reconstruction of large segmental defects mainly due to infection and nonunion is 25%.37,

38

Demineralized bone matrix provides a supportive matrix for

differentiation and maturation of osteoprogenitor cells but it fails to provide rigidity for
segmental defects.39 Ceramics and polymers and their composites have been used to
generate constructs matrices for regeneration of load-bearing bone defects.40

In

particular, calcium phosphate (CaP) ceramics have attracted much attention as a bone
substitute due to their osteoconductivity and osteointegrative properties41, 42 but they are
brittle in tension and shear.43, 44

1

Barati, D., et al., Effect of Organic Acids on Calcium Phosphate Nucleation and Osteogenic
Differentiation of Human Mesenchymal Stem Cells on Peptide Functionalized Nanofibers.
Langmuir, 2015. 31(18): p. 5130-5140.
Reprinted here with permission of publisher.
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Fiber-reinforced composites composed of calcium phosphates and degradable
polymers can potentially have superior properties than their individual components but
their properties are limited by the amount of CaP crystals that can be incorporated in the
composite matrix.45-49 There is a need for composite biomaterials that can stabilize the
regenerating volume, have tunable resorption, and support differentiation and maturation
of osteoprogenitor cells.
Mineralization in bone is mediated by extracellular matrix (ECM) proteins rich in
glutamic acid sequence.50, 51 In previous studies, we demonstrated that CaP contents as
high as 200% (based on fiber weight) can be achieved on nanofiber microsheets by
combining surface functionalization of the nanofibers with glutamic acid peptides and
using a layer-by-layer CaP deposition approach to overcome the limited penetration of
calcium and phosphate ions in the microsheets. The CaP content achieved in our previous
study was higher than that of cancellous bone (190%)52 but lower than the compact bone
(>250%).10 Carboxylate-rich organic acids account for 5.5% of the organic matter in bone
and citric acid plays a significant role in controlling crystallite size, growth and the extent
of mineralization in the natural bone.53 Recently, it was reported that the spacing between
the carboxylate groups in citric acid matches the spacing between calcium ions in the
growing CaP nanocrystals.53-57 Citrate ions in the CaP nucleation solution inhibit the
formation of large and stable crystals in solution58 and catalyze CaP nucleation on
surfaces.59
The objectives of this work was to investigate the effect of supplementing the
nucleation medium with organic acids on the extent of CaP nucleation on the surface of
12

functionalized nanofiber microsheets and osteogenic differentiation of human
mesenchymal stem cells (hMSCs) seeded on the surface of functionalized nanofiber
microsheets through the following approach. The CaP nucleating peptide Glu-Glu-GlyGly-Cys (EEGGC) was conjugated to relatively low molecular weight poly(DL-lactide)
to produce a LMPLA-GLU conjugate. LMPLA-GLU conjugate was mixed with high
molecular weight PLA and electrospun to generate aligned GLU-functionalized PLA
nanofiber microsheets. The microsheets were incubated in concentrated simulated body
fluid (SBF) supplemented with an organic acid to nucleate and grow CaP crystals on the
surface of nanofibers. Citric acid (CA), hydroxycitric acid (HCA), tartaric acid (TART),
malic acid (MA), salicylic acid (SalA) and ascorbic acid (AsA) were selected to tested
organic acids with a range of carboxylic acid and hydroxyl groups.

Figure 2.1. Nucleation of CaP crystals on the surface of nanofibers a. without addition of
chealting agent, b. with addition of chelating agent such as citric acid

13

Carboxylic acid-rich organic acids like citric and malic acids account for 5.5% of the
organic matter in natural bone.53 All tested organic acids are naturally present in fruit and
vegetables. CA is the dominant organic acid in citrus fruits while MA is found in apple
and pear.60 Tomato contains 9% CA, 4% MA, and 0.5% AsA based on dry mass.61 Rice
and soybean contain SalA62 while grapes and grapefruit are a major source of TART and
HCA.63,

64

The CaP nucleated microsheets were characterized with respect to particle

size, crystallite size, percent crystallinity, calcium to phosphate ratio, CaP content, and
compressive modulus. Next, CaP nucleated microsheets were seeded with hMSCs and
cultivated in osteogenic medium. The cell-seeded microsheets were characterized by cell
number, alkaline phosphatase (ALP) activity, and calcium content with incubation time.
Results show that the addition of HCA, CA, and TART to the nucleation solution
significantly increased the CaP content of the microsheets whereas only the addition of
CA and AsA to the nucleation solution significantly increased osteogenic differentiation
of hMSCs seeded on the microsheets.
2. Experimental
2.1. Nanofiber Electrospinning
The solution for electrospinning was prepared by dissolving 8 wt% PLA and 1.5
wt% LMPLA-GLU in HFIP (there was no LMPLA-GLU in “without GLU” samples” )
as we previously described.42 The electrospinning solution loaded in a 1 mL syringe was
injected through a 21-gauge needle (PrecisionGlide, 0.7 mm I.D., Becton-Dickinson,
Franklin, NJ) via a KDS100 syringe pump. The positive and ground electrodes of the
high-voltage power source were connected to the needle and the custom-built rotating
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wheel, respectively.42 The aligned nanofibers were electrospun using a 0.8 mL/h injection
rate, 20 kV electric potential, 7.5 cm needle-to-needle distance, and wheel diameter and
rotation speed of 20 cm and 1800 rpm, respectively, as we previously optimized.65-67 The
collected aligned nanofiber microsheet from a 0.8 mL solution had a thickness of 6 µm.
The average size of the aligned fibers was 200 ±60 nm.42 The electrospun PLA/LMPLAGLU nanofibers are hereafter denoted by NF.
2.2. . Mineralization of NF in Modified Simulated Body Fluid
A stock solution of 10-fold concentrated SBF (10xSBF) was prepared by dissolving
NaCl, KCl, CaCl2•H2O, MgCl2•6H2O, NaH2PO4 in distilled deionized (DI) water as
described.42 Next, one of the organic acids was added to the solution in concentrations
ranging from zero to 15 mM. Molecular structure and pKa value of the organic acids are
given in Table 1. Then, the pH of the solution was adjusted to 7.4 by addition of sodium
bicarbonate (NaHCO3) to the mineralization solution. The solution was maintained at
ambient conditions for 15-45 min to equilibrate and solution-nucleated CaP crystal was
removed by filtration with a 220 nm pore-size filter. Next, the nanofiber microsheets
were submerged in the organic acid-supplemented 10xSBF with agitation on an orbital
shaker for 12 h. The containers were sealed with Parafilm to prevent diffusion of CO2
from the atmosphere and maintain a constant solution pH. The nucleation solution was
changed every 6 h to maintain a constant concentration of calcium and phosphate ions in
solution with incubation time. The NF microsheets mineralized in 10xSBF solution
supplemented with TART, HCA, CA, MA, AsA and SalA are hereafter denoted by
TART, HCA, CA, MA, AsA and SalA, respectively.

15

2.3. Characterization of CaP-Nucleated Nanofiber Microsheets
The extent of CaP nucleation and growth on NF microsheets was measured using a
QuantiChrom calcium assay (Bioassay Systems, Hayward, CA) according the
manufacturer’s instructions.42

Table 2.1. Molecular structure and pKa of the organic acids.

Briefly, the calcium content of 1 mg NF microsheet was dissolved in 0.4 mL of 1M
HCl. Next, 5 µL aliquot of the suspension was added to 200 µL of the kit working
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solution. After 3 min incubation at 37°C, absorbance was measured on a Synergy HT
plate reader at a wavelength of 612 nm and correlated to the equivalent amount of Ca2+
using a calibration curve constructed from reference solutions with known Ca2+
concentrations. The total CaP content was determined from the measured Ca2+ content
and calcium to phosphate (Ca/P) ratio obtained from energy-dispersive X-ray spectrum
(EDS) of the sample. The measured CaP content was divided by the weight of NF sheet
to determine CaP weight percent in each sample with incubation time in nucleation
solution. The CaP-nucleated nanofiber microsheets were imaged with a VEGA3 SBU
variable pressure scanning electron microscope (SEM; Tescan, Kotoutovice, Czech
Republic) at an accelerating voltage of 8 KeV. Samples were coated with gold using a
Denton Desk II sputter coater (Moorestown, NJ) at 20 mA current for 75 sec. The
average fiber size of the microsheets and CaP particle size were determined from the
analysis of SEM images using the ImageJ software (National Institutes of Health,
Bethesda, MD) as described previously.42 An EDS system (Tescan) connected to the
SEM was used to analyze the samples for elemental composition and Ca/P ratio of the
samples as described.68
Crystallinity and crystallite size of the nucleated CaP on microsheets were measured
by wide-angle X-ray diffraction (XRD) using a Philips 405S5 diffractometer (Eindhoven,
Netherlands) as we previously described.68 The diffraction spectrum was collected with a
CuKα radiation source (λ=1.54059 Å) at 30 KeV over Bragg angles (2Ө) ranging from
10 to 50 degrees with a step size of 3 degrees/min-1. Average crystallite size (L) of CaP
particles nucleated on the microsheets was calculated from the XRD spectrum using
Scherrer equation 69, 70
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L=

Kλ
β cos θ

(1)

where K is a shape factor with a value close to unity, λ is the X-ray wavelength, β
is full width at half maximum (FWHM) of the peak at the diffraction angle θ . The (002)
reflection peak (2Ө=25.8) in the XRD spectrum was used to calculate crystallite size of
the CaP particles as described.

71, 72

The fraction of crystalline phase in the CaP

nanoparticles ( X C ) was calculated using the following equation developed for calcium
phosphate crystals73

XC ≈1−

ν 112 / 300

(2)

I 300

where I300 is intensity of the (300) diffraction peak and ν112 / 300 is intensity of the
hollow region between (112) and (300) diffraction peaks in the XRD spectrum of the
samples.
For determination of compressive modulus, a 10 layered nanofibrous microsheets
with the overall thickness of 60 µm was loaded on the Peltier plate of an AR2000
rheometer (TA Instruments, New Castle, DE) and subjected to a uniaxial compressive
force at a displacement rate of 7.5 mm/s. The slope of the linear fit to the stress–strain
curve for 5–10% strain was taken as the elastic modulus (E) of the mineralized matrix as
we previously described.74 For determination of mass loss, the annealed samples were
incubated in simulated body fluid (SBF) at 37ºC and under mild agitation. At each time
point, samples were removed from SBF, washed three times with DI water and dried
under vacuum. The dry sample weight was measured and compared with the initial dry
weight to determine the fractional mass remaining as described 75.
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2.4. Cell Seeding on Mineralized Microsheets
hMSCs were cultivated at 5000 cells/cm2 in a high glucose DMEM medium
supplemented with 10% FBS, 100 units/mL penicillin and 100 µg/mL streptomycin
(basal medium) with medium refreshment every three days. After reaching 70%
confluency, the cells were detached with 0.1% trypsin- 0.03% EDTA and sub-cultivated
at a ratio of 1:3 for <5 passages, according to supplier’s instructions. For cell seeding,
edges of the microsheets on 12 mm circular glass coverslips were covered with a
medical-grade silicone sealant (Dow Corning, MI) to prevent separation of the
microsheet from coverslip in the cell culture medium. The microsheets were sterilized by
ultraviolet (UV) radiation for 1 h followed by immersion in 70% ethanol for 30 min and
washing three times with sterile PBS. We have previously shown that fiber alignment and
size, or attachment of CaP nanoparticles nucleated on the fibers are not affected by the
sterilization procedure.42 After incubation in basal medium for 1 h, each microsheet
sample was seeded with 60 µL hMSC cell suspension (1.7x106 cells/mL in basal
medium) at a surface density of 1x105 cells/cm2. After incubation for 24 h for cell
attachment, the medium was replaced with osteogenic medium (basal medium plus 100
nM dexamethasone, 50 µg/mL ascorbic acid, 10 mM ß-glycerophosphate). CA
microsheets seeded with hMSCs and incubated in basal medium was used as the control
group. The hMSC-seeded microsheets were incubated in a humidified 5% CO2 incubator
for 21 days.
2.5. Osteogenic Differentiation of Cell-Seeded Mineralized Microsheets
At each time point (0, 7, 14 and 21 days), cell-seeded microsheet samples were
washed with serum-free DMEM for 8 h to remove serum proteins followed by washing
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with PBS. Next, samples were lysed with 10 mM Tris supplemented with 0.2% triton in
PBS and the lysed samples were used for measurement of DNA content, ALP activity,
and calcium content. Double-stranded DNA content, ALP activity and calcium content of
the samples were measured with Quant-it PicoGreen, QuantiChrom ALP and
QuantiChrom Calcium Assays, respectively, as we previously described.

42, 75

To

determine the extent of mineralization of the samples by the seeded hMSCs at each time
point, the measured calcium intensities at time zero was used a baseline to subtract the
calcium contribution from the CaP-nucleated fibers prior to cell seeding. The measured
ALP activities and calcium contents were normalized to cell number by dividing to DNA
content at each time point. For imaging the extent of hMSC-induced mineral deposition,
the microsheets were stained with Alizarin red using the following procedure. The cells
on the microsheets were fixed with 10% paraformaldehyde. Next, the fixed samples were
covered with a solution of Alizarin red, prepared according to the manufacturer’s
instructions, and incubated in the dark at ambient conditions for 20 min. Then, a Nikon
Optiphot epifluorescence microscope was used to image the samples for extent of nodule
formation and the images were analyzed for average size of the nodules by the ImageJ
software as we previously described 42.
2.6. Statistical analysis.
Data are expressed as means ± standard deviation. All experiments were done in
triplicate. Significant differences between groups were evaluated using a two-tailed
Student's t-test. A value of p<0.05 was considered statistically significant.
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3. Results
3.1. CaP nucleation on the mineralized microsheets
Figure 2.2a and 10b show the percent CaP nucleated on the microsheets with GLU
(1a) or without GLU (1b) as a function of organic acid concentration in 10xSBF. CaP
content of the GLU incorporated microsheets incubated for 12 h in 10xSBF without the
addition of organic acids was 160±20%. That was significantly higher than the CaP
content of the “without GLU” microsheets incubated for 12 h in 10xSBF (40%, see
Figure 2.2b). SalA and AsA did not significantly affect CaP content of “with GLU”
microsheets at concentrations <4mM. CaP content of the “with GLU” microsheets
increased to 170±10% and 175±5%, respectively, as SalA and AsA concentrations
increased to 10 mM and CaP content remained unchanged with further increase in SalA
or AsA concentration. CaP content of the “with GLU” microsheets peaked at 200%±20
as MA concentration increased to 8 mM and then decreased to 185%±15 at MA
concentration of 15 mM. CaP content of the “with GLU” microsheets incubated with CA,
TART, and HCA increased with organic acid concentration, peaked at 6 mM
concentration, and then decreased with increasing organic acid concentration. CaP
content of the “with GLU” microsheets incubated with 6mM concentration of CA,
TART, and HCA was 225±30%, 225±20% and 240±25%, respectively, but CaP content
decreased to 200±20%, 205±15% and 215±20% at 15 mM organic acid concentration.
The CaP content of “without GLU” microsheets increased from 40 wt% to a maximum of
103, 114, 133, 155, 160 and 175 wt% when the nucleation medium was supplemented
with SalA, AsA, MA, CA, TART and HCA, respectively. The peak CaP content of the
“with GLU” microsheets incubated with 6 mM HCA was comparable with CaP content
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of the natural compact bone.10 Figure 2.3 shows CaP content of the “with GLU”
microsheets as a function of incubation time in 10xSBF supplemented with one of the
organic acids at a concentration corresponding to the peak CaP content in Figure 2.2. In
Figure 2.3, “None” represents the group without addition organic acids and Ctrl
represents the group without addition of neither organic acid nor GLU. CaP content of
the microsheets monotonically increased with incubation time in the first 16 h and
reached a plateau at longer times. CaP content did not change significantly when
incubation time was increased from 16 to 24 h for all organic acids and the plateau CaP
content was highest for HCA supplemented 10xSBF at 244±10% and lowest for SalA at
174±8%. Results in Figures 2.2-2.3 show that the addition of HCA to 10xSBF had the
greatest effect on CaP content of the microsheets followed by TART, CA, and MA.
Further, the optimum concentration and optimum incubation time was 6 mM and 12 h,
respectively.

Figure 2.2. Effect of organic acid concentration added to the concentrated SBF on CaP
content of DL-PLA nanofiber microsheets (a) with and (b) without GLU for different organic
acids after 16 h incubation.
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Figure 2.3. Effect of incubation time in the concentrated SBF supplemented with different
organic acids on CaP content of DL-PLA nanofiber microsheets at organic acid concentration
corresponding to maximum CaP content in Figure 2.2.

Figure 2.4 shows XRD spectra of the mineralized “with GLU” microsheets after
incubation for 12 h in 10xSBF supplemented with optimum concentration of the organic
acid (Figure 2.2a). The XRD spectra of pristine nanofiber microsheet without CaP
nucleation (PLA) and pure hydroxyapatite (HA) are also included in Figure 2.4. The
broad diffraction peak in the spectrum of pristine PLA microsheet centered at 2Ө = 16° is
characteristic of the amorphous poly(DL-lactide).76 Calcium phosphates that mineralize
from solution at ambient conditions are HA, amorphous calcium phosphate (ACP),
dicalcium phosphate dihydrate (DCPD), and octacalcium phosphate (OCP).

77, 78

The

relatively sharp diffraction peaks in the spectra of HA and mineralized microsheets
centered at 2Ө = 25.8°, 31.8°, 32°, 33°, and 46° corresponded to (002), (211), (112),
(300) and (222) planes of HA, respectively. 72, 76-78 The relatively broad diffraction peak
overlapping the HA peaks at 2Ө = 31.8°, 32°, and 33°, which was absent in the spectrum
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of HA, was due to the formation of ACP in the mineralized microsheets.70,

77

The

characteristic diffraction peaks for crystalline OCP (2Ө = 16° and 24°) and DCPD (2Ө =
29.2°, 34.4°, and 11.4°) were absent in the spectra of mineralized microsheets72, 77, 78.

Figure 2.4. X-ray diffraction spectra of DL-PLA nanofiber microsheets with GLU incubated
in the concentrated SBF supplemented with HCA, TART, CA, MA, AsA, and SalA organic acids
for 16 h at the concentration corresponding to the maximum CaP content in Figure 2.3.

The EDS spectra of the mineralized “with GLU” microsheets incubated in 10xSBF
for 12 h with optimum concentration (Figure 2.2) of HCA, TART, CA, MA, AsA, and
SalA are shown in Figures 2.5a through f. The elemental Ca/P ratio calculated from the
calcium and phosphorous peaks in Figure 2.5 and EDS data for “without GLU”
microsheets (data not shown) are presented in Table 3 together with crystallinity and size
of the crystallites (XRD images) and size of the CaP particles nucleated on nanofibers of
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the microsheets (SEM images). Crystallinity of “with GLU” microsheets incubated in
10xSBF without organic acids was 21±2%. TART and AsA incubated microsheets
(TART and AsA) had the highest and lowest percent crystallinity, respectively, among all
organic acids with 39±2% and 20±2%. SalA, HCA, CA, and MA incubated microsheets
(SalA, HCA, CA, and MA) had percent crystallinity of 23±1%, 31±1%, 30±1%, and
35%±3, respectively, which was in the range of crystallinity of cortical and cancellous
bone (33-37%).79 The size of crystallites ranged between 31±2 and 62±4 nm with TART
and Sal having the lowest and highest crystallite size, respectively. In comparison, the
crystallite size for the “with GLU” microsheets mineralized in the absence of organic
acids was 60±5 nm. Ca/P ratio of the microsheets ranged between 1.68±0.03 for TART
and 1.91±0.05 for AsA with the microsheets mineralized in the absence of organic acids
having a Ca/P ratio of 1.88±0.1. TART incubated “with GLU” microsheets had Ca/P
ratio of 1.68 which was closest to that of natural bone at 1.67

79

followed by HCA and

CA with Ca/P ratio of 1.71 and 1.77, respectively. Crystals formed on “without GLU”
microsheets had lower crystallinity, higher Ca/P ratio and larger crystallite size compared
to the ones formed on “with GLU” microsheets.
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Figure 2.5. EDS spectra of DL-PLA nanofiber microsheets incubated in the concentrated
SBF supplemented with HCA, TART, CA, MA, AsA, and SalA organic acids for 16 h at the
concentration corresponding to the maximum CaP content in Figure 2.2.

Figure 2.6a-b shows the mass loss of the mineralized “with GLU” microsheets with
incubation time in SBF at 37°C. The mass remaining of pristine PLGA and PLA NFs was
0 % and 68%±5, respectively, whereas the mass remaining of mineralized NFs ranged
between 85 %±2 and 93 %±1 after 35 days of incubation in SBF.
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Table 2.2. Percent crystallinity, calcium to phosphate (Ca/P) ratio, crystallite size, and
particle size of calcium phosphates particles nucleated on DL-PLA nanofiber microsheets (a) with
and (b) without GLU.

The mass losses are magnified in Figure 2.6b to show the effect of organic acid
added to 10xSBF on mass loss of the mineralized microsheets. HCA with 12 %±2 mass
loss had the slowest degradation while SalA with 19 %±3 mass loss had the fastest
degradation among mineralized NFs after 42 days.
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Figure 2.6. (a) Mass loss of DL-PLA nanofiber microsheets incubated in the concentrated
SBF supplemented with HCA, TART, CA, MA, AsA, and SalA organic acids for 16 h at the
concentration corresponding to the maximum CaP content in Figure 2.2. In (b) the y-axis is
expanded (100-95% mass remaining) to show mass remaining for the mineralized microsheets.
PLGA NF and PLA NF are PLGA and DL-PLA nanofiber microsheets with GLU and without
incubation in SBF. There was not a significant pair-wise difference between the mass loss of CA
and MA, CA and TART, and TART and MA groups by ANOVA test. There was a significant
pair-wise difference between the mass remaining of other groups. Error bars correspond to
means±1 SD for n=3.

SEM images in Figure 2.7 and Figure 2.8 show the effect of organic acid added to
10xSBF on size and distribution of the CaP nanoparticles nucleated on nanofibers of the
“with GLU” and “without GLU” microsheets respectively. The average size of the
nucleated CaP nanoparticles determined from the SEM images is presented in Table 3.
The average particle size on “with GLU” microsheets ranged from 95±8 nm for TART to
180±9 nm for SalA whereas the average particle size on “without GLU” microsheets
ranged from 110±9 nm for TART to 270±33 nm for SalA. The size of the CaP crystals
formed on both “with GLU” and “without GLU” microsheets in the organic acid
incorporated solutions were significantly lower than the size of the ones formed in the
absence of organic acids (None groups in Figure 2.7 and Figure 2.8). The number density

28

of CaP nanoparticles in AsA and SalA samples was lower than that of the other organic
acid incorporated samples, consistent with the lower CaP content of AsA and SalA
microsheets (see Table 4). The effect of organic acid in CaP nucleation medium on
compressive modulus of the microsheets is presented in Table 4. Modulus of the “with
GLU” and “without GLU” microsheets increased by 2.9 and 10.0 folds with CaP
nucleation in the absence of organic acids in the nucleation solution (None group in Table
3). The modulus of both “with GLU” and “without GLU” microsheets significantly
increased with incorporation of organic acids within the nucleation solution. Furthermore,
the modulus of “with GLU” microsheet was significantly higher than the one for
“without GLU” microsheet in the presence or absence of organic acids.

HCA “with

GLU” microsheets with CaP content of 240±10 wt% had the highest modulus of 260±40
MPa compared to other mineralized microsheets which was 21.7-fold higher than the
modulus of pristine DL-PLA microsheets

Table 2.3. Maximum CaP content and compressive modulus of DL-PLA nanofiber
microsheets with and without GLU incubated in the concentrated SBF supplemented with
different organic acids.

.
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Figure 2.7. SEM images of DL-PLA nanofiber microsheets with GLU incubated in the
concentrated SBF supplemented with HCA (a), TART (b), CA (c), MA (d), AsA (e), and (f) SalA
for 16 h at the concentration corresponding to the maximum CaP content in Figure 2.2. None
SEM image is DL-PLA nanofiber microsheets with GLU incubated in the concentrated SBF
without the addition of organic acids for 16 h at the concentration corresponding to the maximum
CaP in Figure 2.2.

3.2. Osteogenic differentiation of hMSCs on nanofiber microsheets
hMSCs were seeded on mineralized microsheets and cultured in complete osteogenic
medium

(basal

medium

plus

dexamethasone,

glycerophosphate).
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(0.3
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ß-

Figure 2.8. SEM images of DL-PLA nanofiber microsheets without GLU incubated in the
concentrated SBF supplemented with HCA (a), TART (b), CA (c), MA (d), AsA (e), and (f) SalA
for 16 h at the concentration corresponding to the maximum CaP content in Figure 2.2. None
SEM image is DL-PLA nanofiber microsheets without GLU incubated in the concentrated SBF
without the addition of organic acids for 16 h at the concentration corresponding to the maximum
CaP in Figure 2.2.

Experimental groups were hMSCs seeded on “with GLU” microsheets mineralized
in the absence of organic acids (None) or presence of CA, AsA, SalA, HCA, MA and
TART organic acids within the nucleation solution. hMSCs seeded on CA group and
cultured in basal medium (CA-BM) was used as a control. DNA content of hMSCs
cultured on the NF microsheets is shown in Figure 2.9. DNA content of the hMSCs in the
control CA-BM group (black diamond) increased slightly with incubation time while the
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DNA content of groups incubated in osteogenic medium decreased slightly with time.
We have previously shown that at high initial cell seeding density used in our
experiments, cell content of the microsheets decreases with incubation time as the cells
undergo osteogenic differentiation.42 DNA content of hMSCs seeded on CA, AsA, SalA,
HCA, MA and TART with a seeding density of 105 cells/ cm2 and incubated in
osteogenic medium decreased slightly over 7 days of culture (Figure 2.9a) while the
DNA content of hMSCs seeded on the same groups with two orders of magnitude lower
seeding density (103 cells/cm2) increased significantly after 7 days of culture within the
osteogenic medium.
ALPase activity of hMSCs seeded on NF microsheets is shown in Figure 2.9b.
ALPase activity of hMSCs seeded on CA-BM group incubated in basal medium did not
increase significantly with time (black diamond). ALPase activity of hMSCs in CA, AsA
and SalA groups peaked to the value of 5800±300, 5300±250 and 4800±150 IU/mgDNA,
respectively at day 14, which was higher than that of None group with 4500±300
IU/mgDNA at day 14. The peak value of ALPase activity for hMSCs seeded on HCA,
MA and TART microsheets was 3800±200, 3200±100 and 3000±150 IU/mgDNA,
respectively, after 14 days which was lower than that for None group. Calcium content of
hMSCs seeded on mineralized NFs and cultured in osteogenic medium (basal medium for
CA-BM) group is shown in Figure 2.9c. All calcium content values were subtracted from
the values at day 1 to isloate the Ca deposited by cells from CaP deposited on fibers prior
to cell seeding. Calcium content of the hMSCs seeded on CA-BM did not significantly
change after 21 days of incubation in basal medium. The calcium content of all other
groups increased slightly from day 4 to 7 and then increased monotonically over 21 days.
32

The calcium content of CA, AsA was 1200±100 and 1100±100 (mg/mg DNA)
respectively after 21 days of incubation, higher than calcium content of None group
(980±85 mg/ mg DNA). Calcium content of SalA, did not have a significant difference
with that of None group at day 21. Calcium content of HCA, MA and TART groups was
750±60, 610±50 and 550±55 mg/mgDNA, respectively, after 21 days of incubation
which was lower than the calcium content of None group.

Figure 2.9. DNA content (a) ALP activity (b) and calcium content (c) of hMSCs seeded on
mineralized DL-PLA nanofiber microsheets with GLU as a function of incubation in osteogenic
medium. CA-BM group (black diamond) is CA group incubated in basal medium, group
incubated in osteogenic medium. Error bars correspond to means±1 SD for n=3.

Image in Figure 2.10 show Alizarin Red Staining of hMSCs seeded on “with GLU”
mineralized NF microsheets and cultured in osteogenic medium for 21 days. Controls
included NF microsheets without CaP deposition and without hMSCs seeding (NF, 11i),
NF microsheets with CaP deposition and without hMSCs seeding (NF+CaP, 11h) and NF
microsheets with CaP deposition in the absence of organic acids within the nucleation
solution and seeded with hMSCs (None, 11g). The presence of dark red areas in Figure
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2.10a-g as opposed to Figure 2.9h and 2.10i showed the contributing effect of hMSCs to
mineralization. A relatively high density of orange-red areas on the CA, AsA, SalA and
None groups qualitatively confirmed a higher Calcium content (See Figure 2.10c) of the
aforementioned groups compared with that of MA, TART and HCA groups. Formation
of bone nodules, three dimensional specifically mineralized and organized structures with
proliferation, differentiation and mineralization stages of hMSCs simultaneously

80

, was

observed as large dark spots only on the CA group (see Figure 2.10b). The number
density and total area of bone nodules on the CA group was 86 counts/cm2 and 1.8 ± 0.2
mm2/cm2. Dark spots on the AsA and None groups (see Figure 2.10e and 2.10g) were
smaller (<35 µm) to be considered as bone nodules based on the previous reports 80, 81 .
4. Discussion
In this work, we investigated the effect of organic acids with different number of
hydroxyl and carboxylic acid groups (see Table 1) in the simulated body fluid on the
extent of CaP nucleation on nanofiber microsheets . An attractive approach to retard CaP
crystal nucleation in solution and enhance nucleation on the fiber surface is to increase
the solubility of calcium and phosphate ions in the nucleation solution.78 Carboxylate-rich
organic acids like citric acid which account for 5.5% of the organic matter in the natural
bone,53 inhibits CaP crystal nucleation in solution.58, 59 Citric acid (  ) with three
carboxylate groups is ionized to citrate ion (   ) (hereafter referred as Cit) in
10xSBF nucleation medium.
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Figure 2.10. Alizarin red staining of hMSCs seeded on mineralized DL-PLA with GLU and
incubated in osteogenic medium for 21 days. NF+CaP and NF groups are mineralized and
pristine nanofiber microsheets, respectively.

Subsequently, the citrate ions are adsorbed on the surface of positively charged
calcium ions to form a Ca-Cit complex. The negatively charged Ca-Cit complex is
electrostatically repelled by the phosphate ions (PO43-)

53, 58, 82

. The stability of Ca-Cit

complex in solution depends on Cit concentration with the chelated Ca(Cit)- complex
formed at low Cit concentrations72 and the stable [Ca(Cit)2]-4 complex formed at high Cit
concentrations.59 Therefore, the presence of Cit ions at low concentration inhibits the
formation of CaP crystals in the nucleation solution, effectively increasing the probability
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of CaP nucleation on GLU sites on the surface of nanofibers. Consequently, CaP content
of the NF microsheets increased with increasing CA concentration from zero to 6 mM in
the presence of Ca(Cit)- complex. As the CA concentration was increased to values >6
mM, the stable [Ca(Cit)2]-4 formed at high concentrations inhibited CaP nucleation on
the fiber surface.59 HCA, TART, MA, SalA, and AsA organic acids form complexes with
Ca ions in the nucleation solution through their carboxylate groups similar to that of citric
acid.83 Therefore, the biphasic trend of CaP content of the NF microsheets observed in
Figure 2.2 can be attributed to a change in the stability of organic acid-calcium complex
with organic acid concentration in the nucleation solution.
The maximum CaP content of “with GLU” NF microsheets after 12 h incubation in
10xSBF supplemented with HCA, TART, CA, MA, AsA, and SalA was 240±10%,
225±8%, 225±10%, 177±15%, 203±12%, and 170±6=7%, respectively, compared to
160±12% without organic acid. The difference in peak CaP contents can be attributed to
the different number of carboxylic acid and hydroxyl groups in the organic acids. Higher
number of carboxylate groups in the organic acid increased chelation between calcium
ions and organic acid molecules in the nucleation solution83 whereas higher number of
hydroxyl groups in the organic acid enhanced hydrogen bonding interaction between the
Calcium-organic acid complex and the carboxylic acid groups and electronegative groups
present on GLU as well as fiber surface.

59

According to Figure 2.2a and 1.1b, the CaP

content of both “with GLU” and “without GLU” NF microsheets increased significantly
with addition of organic acids to the nucleation solution. However, the peak values for
calcium content were higher in “with GLU” microsheets. Therefore, while Calcium-
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organic acid complex can bind to the fiber surface in the absence of GLU, the presence of
GLU contributed to the CaP nucleation significantly.
CaP content of the NF microsheets decreased as the organic acid in the nucleation
medium was changed from HCA with three carboxylic acids to TART and MA with two
carboxylic acids and SalA with one carboxylic acid group (see Tables 2 and 4). Further,
HCA with two hydroxyl groups resulted in higher CaP of the microsheets when added to
the nucleation medium compared to CA with a single hydroxyl group although both
organic acids had three carboxylic acid groups. Similarly, CaP content of the microsheets
incubated in SBF supplemented with TART (two hydroxyl groups) was higher than MA
with one hydroxyl group while both organic acids had the same number of carboxylic
acids. The higher CaP content of the microsheets incubated in SBF supplemented with
AsA compared with MA was attributed to the higher number of hydroxyl groups in AsA
(three for AsA versus one for MA). CaP content of the microsheets was 240% after 12 h
incubation in HCA-supplemented 10xSBF which was higher than the CaP content of
natural cancellous bone (190%)52 and cortical bone (230%).10 The incubation time to
reach 95% of the plateau CaP content was 10 h which was significantly lower than the
reported 4 days of incubation for CaP nucleation on the collagen nanofibers in 1.5xSBF
supplemented with CA.59
XRD results demonstrated that the CaP nucleated on the NF microsheets was a
mixture of HA and ACP. Further, the deviation of Ca/P ratio from that of pure HA (1.67,
see Table 3) increased with decreasing crystallinity of the nucleated CaP on the
microsheets. Therefore, the deviation of Ca/P ratio from that of HA was related to the
changes in the amorphous phase of the CaP particles with a Ca/P ratio in the 1.2-2.2
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range).

72, 77, 78, 84

The crystallinity of CaP particles on NF microsheets was highest when

the nucleation medium was supplemented with TART or MA having two carboxylic acid
groups which can be attributed to an optimal spacing of Ca ions on the surface of the
growing crystals. The relatively large CaP particle size and crystallite size in microsheets
incubated in AsA and SalA supplemented SBF (Table 3) can be attributed to the lower
inhibitory effect of those organic acids on crystal growth. Since AsA and SalA had only
one carboxylic acid group with a net negative charge of one, the propensity for complex
formation with Ca ions on the fiber surface for AsA and SalA was lower than other
organic acids with two or more carboxylic acid groups (see Table 3). The number of
crystallites per CaP particle on the microsheets was calculated from the particle size,
crystallite size, and crystallinity data in Table 3. The number of crystallites per particle on
the microsheets incubated in SBF supplemented with HCA, TART, CA, and MA was 11,
11, 10 and 11, respectively, whereas that number was 4 and 5 for AsA and SalA.
Therefore, the number of growing crystals on the surface of NF microsheets decreased
and the size increased for those organic acids with lower inhibitory effect toward crystal
growth (see Table 2.3 and Figure 2.7). Since the number of crystallites per particle was
greater than unity for all organic acids, the nucleated particles had a polycrystalline
structure interconnected by an amorphous phase.72
For equal CaP content, TART incubated microsheets with higher crystallinity had
higher compressive modulus than CA incubated microsheets (see Table 4). The slower
degradation of mineralized microsheets indicated that the CaP nanoparticles had slower
degradation than the DL-PLA nanofibers.43 The difference in degradation of the
mineralized microsheets (Figure 2.6b) was related to differences in crystallinity and CaP
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content. For example, microsheets incubated with AsA supplemented SBF with lowest
crystallinity but higher CaP content than SalA and MA incubated microsheets had fastest
mass loss among all microsheets. Conversely, microsheets incubated with HCA
supplemented SBF with highest CaP content but lower crystallinity than TART and MA
incubated microsheets had slowest mass loss among all microsheets.
The difference between DNA content of hMSCs seeded on the surface of mineralized
fibers 1 day after culture could be related to the differences between the surface
properties of mineralized fibers. It has been reported elsewhere that the surface adhesion
of human gingival fibroblasts cells on an amorphous HA (~25% crystallinity) coating
surface was higher than that of surfaces coated with higher crystalline HA (~ 63% and
97% crystallinity)

85

. Therefore, a higher DNA content of AsA, Ca and SalA groups

compared with those of MA, TART and HCA groups could be due to a lower
crystallinity of CaP particles hence higher adhesion of cells to the surface of former
groups. Based on ALPase and calcium measurements, the presence of CA or AsA in the
nucleation solution of microsheets had a positive effect on osteogenic differentiation of
hMSCs while the presence of SalA did not have a significant effect and the presence of
HCA, MA and TART within the nucleation solution was counterproductive in osteogenic
differentiation of hMSCs. The contributing effect of CA to osteogenic differentiation of
hMSCs was consistent with a reported contributing effect of calcium citrate in bone
healing 86. Further, it was shown elsewhere that an incorporation of CA into a cellulose
based hydrogel improved osteogenic differentiation of hMSCs

87

. In addition, It is well

established that the presence of AsA stimulates the osteogenesis through integrinmediated intracellular signaling

88

. Addition of CA to the nucleation solution also
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stimulated the formation of nodules >100 µm in size (Figure 2.10). Schecroun et al.
reported that dexamethasone in the osteogenic medium inhibited nodule formation by
hMSCs in 2D culture.80 Our results indicate that the addition of CA to the nucleation
solution hence the presence of citrate ion on the fiber surface stimulates nodule formation
by hMSCs even in the presence of dexamethasone within the culture medium.
5. Conclusion
In this work, the effect of organic acids added to the simulated body fluid on CaP
nucleation and osteogenic differentiation of human MSCs on nanofiber microsheets
functionalized with a CaP nucleating glutamic acid peptide. Glutamic acid-functionalized
aligned DL-PLA nanofiber microsheets were electrospun by blending high molecular
weight DL-PLA with low molecular weight PLA conjugated with EEGGC peptide. The
nanofiber microsheets were incubated in concentrated SBF supplemented with different
organic acids for nucleation and growth of CaP nanoparticles on the surface of
nanofibers. Organic acids included citric acid (CA), hydroxycitric acid (HCA), tartaric
acid (TART), malic acid (MA), ascorbic acid (AsA), and salicylic acid (SalA). Addition
of organic acids to SBF significantly increased CaP nucleation on the fiber microsheets
and the extent of CaP nucleation depended on the number of carboxylic acid and
hydroxyl groups in the organic acid. HCA-supplemented group had the highest CaP
content at 240±10% followed by TART and CA with 225±8% and 225±10%,
respectively. CaP nanoparticles nucleated on the fiber surface in TART-supplemented
group had Ca/P ratio (1.68) and crystallinity (39%) closet to that of natural bone.
Microsheets in HCA-supplemented group had the highest compressive modulus of
260±40 MPa followed by TART and CA with 225±8 and 225±10 MPa, respectively. The
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presence of CA or AsA in the nucleation solution of microsheets had a positive effect on
osteogenic differentiation of hMSCs while the presence of SalA did not have a significant
effect and the presence of HCA, MA and TART within the nucleation solution was
counterproductive in osteogenic differentiation of hMSCs. CA group also stimulated the
formation of bone nodules on the microsheets.
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CHAPTER 3: ENGINEERING A CORTICAL-BONE-MIMETIC
NANOSTRUCTURED SHELL WITH INTERCONNECTED MICROCANALS
1. Introduction
Biodegradable scaffolds, as key artificial devices widely used in tissue engineering,
aim to provide a desirable micro-environment that allows neo-tissue to be generated
properly for repairing and replacing damaged tissues or organs. To improve the
performance of tissue scaffolds, various material parameters, e.g. stiffness, porosity and
permeability, have proven particularly crucial to determine the biomechanical
environments within scaffold micro-architectures. The scaffold material and porous
architecture design (here architecture refers to features 10 to 1,000 micrometres in size)
play a significant role in tissue regeneration by preserving tissue volume, providing
temporary mechanical function, and delivering biofactors. Intuitively, the best scaffold
for an engineered tissue should be the ECM of the target tissue in its native state. One of
the crucial characterizations of a tissue engineering scaffold is possessing sufficient
mechanical properties to fill up the void space of the defect and simulating that of the
native tissue. Therefore, scaffolds should provide mechanical and shape stability to the
tissue defect. The intrinsic mechanical properties of the biomaterials used for scaffolding
or their post-processing properties should match that of the host tissue. Recent studies on
mechanobiology have highlighted the importance of mechanical properties of a scaffold
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on the seeded cells. Additionally, a tissue engineering scaffold should provide void
volume for vascularization, new tissue formation and remodeling so as to facilitate host
tissue integration upon implantation. The biomaterials should be processed to give a
porous enough structure for efficient nutrient and metabolite transport without
significantly compromising the mechanical stability of the scaffold. On the one hand,
increasing scaffold stiffness could lead to a potential decrease in porosity and
permeability, which prevents the neo-tissue from proper ingrowth to the bulk of
scaffolds. On the other hand, increasing scaffold porosity might lead to a higher
permeability but the effective stiffness would be sacrificed. Moreover, the biomaterials
should also be degradable upon implantation (with a temporary resistance to
biodegradation upon implantation) at a rate matching that of the new matrix production
by the developing tissue.
Bone is a natural complex porous composite with unique properties of remodelling to
adapt its microstructure to external mechanical stress. Bone is also one of the tissues with
the highest demand for tissue reconstruction or replacement. Cranial, maxillofacial, oral
fractures and large bone defects are currently being treated by using auto- and allografts.
These techniques have limitations in the clinical usage such as immune response, donorsite morbidity, and lack of availability89-91. Therefore, the interest on artificial tissue
grafts were recently considered in order to overcome limitations of traditional allo- or
autografts, such as risk of immune rejection and pathogen transfer, pain and infection, or
limited availability

7, 92

. The overall aim of this study is to develop a much-needed

autograft-bone-mimetic engineered graft as a substitute for allograft bone in
reconstruction of large bone defects. Bioresorbable scaffolds, i.e. porous constructs,
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seeded with the appropriate type of cells, should provide a template for tissue
regeneration, while slowly resorbing, to finally leaving no foreign substances in the body,
thus reducing the risk of inflammation. A three-dimensional (3D) internal geometry,
similar to bone morphology, and the retention of mechanical properties after implantation
are required for scaffolds in order to maintain a tissue space of prescribed size and shape
for tissue formation.
The cortical bone is a hollow center dens shell composed of smaller units called
osteons that have microtube like structures with a central vascular channel inside for
ensuring suitable nutrient/waste transport to the bone tissue 93. Laminated multilayers of
CaP deposited collagen fibers forms the osteon microtubes. The extracellular matrix
(ECM) of bone is a composite that primarily comprises hydroxyapatite (HA) (biological
ceramics) embedded within a collagen matrix (biological polymers) and water (Figure 3.1
a). Carbonated HA Ca10(PO4)6(OH)2 accounts for approximately 70 % of the weight of
bone. The inorganic component provides compressive stiffness to bone. Roughly onethird of the weight of bone is composed of the organic matter, which is primarily type I
collagen and ground substance. Type I collagen fibres are elastic and flexible, and thus
tolerate stretching, twisting, and bending. Therefore, biocompatible and biodegradable
engineered scaffolds which can mimic both nano and microstructure of osteons in cortical
bone tissue would be strong candidates for bone tissue engineering applications.
Numerous methods have been developed and employed to fabricate 3D scaffolds for
tissue engineering applications. Although the conventional fabrication techniques such as
solvent casting, Freeze-drying and Gas foaming/supercritical fluid processinghave
produced scaffolds used in tissue engineering of various types, most of them are
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incapable of producing fully continuous interconnectivity and uniform pore morphology
within a scaffold. Additionally, the pore size, pore geometry and spatial distribution
cannot be precisely controlled in these conventional processes. One of the main
limitations of most conventional fabrication methods is the need of an organic solvent to
dissolve polymers and other chemicals, as well as the use of porogens to create pore
structures. Most solvents and porogens are toxic, and their residues in the scaffold may
cause severe inflammatory responses. Also, the physical configuration of the scaffolds,
which mediate the cell-cell and cell-scaffold interactions, exerts strong influence on the
success of osteogenesis processes in vitro

94, 95

. The success of engineered scaffold

mostly depends on how closely the cell-scaffold interaction mimics that natural tissue in
vivo. Both in vitro and in vivo studies have demonstrated that organic/inorganic
composite fibrous scaffolds which can mimic nanostructure of natural bone, support
attachment, differentiation, and proliferation of osteoblasts or mesenchymal stem cells
(MSCs) and facilitate bone healing

96

. However, investigations regarding the effect of

fibrous composite scaffolds such as osteon-mimetic tubular scaffolds with 3D
morphology on osteogenic differentiation of MSCs are still limited. To this end, we
hypothesized that three dimensional structure of microtubes with well-defined pores
could potentially mimic the microstructure of osteons in cortical bone and induce
osteogenesis of MSCs. In order to test this hypothesis, we investigated the osteogenic
differentiation potential of MSCs when seeded into microtubes engineered from CaP
deposited aligned nanofiber microsheets that have an array of macropores to enhance
diffusion of nutrients. The microtube structure fabricated by wrapping CaP deposited
nanofiber layers around the stainless steel needles upon annealing wrapped nanofiber
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microsheets above glass transation temperature (Tg). The effect of tubular formation of
CaP deposited microsheets on osteogenic differentiation of rat MSCs was investigated by
cytochemical, and mRNA expression. Our results indicate that the 3D microtubes provide
a promising microenvironment that enhances osteogenesis when compared to microsheet
scaffolds.
2. Experimental
2.1. Fabrication of cortical-bone-mimetic scaffolds
CaP-nucleated microsheets (discussed in Chapter 2) were wrapped tightly around a
25 G needle between 10-30 times for form a microtube (Figure 3.1 b). Next, a set of the
microtubes was packed around a stainless steel rod and the assembly was heated to a
temperature above the Tg PLA (85°C) nanofibers to form a rigid, tough, osleoconduetive,
cylindrical shell by fuse the microtubes. After cooling, the rod and microneedles (in the
mierotubes) were removed to obtain a nanostructred cylindrical shell with Haversian-like
microcanals (Figure 3.1 b). Then, an array of circular microholes was drilled by a
scanning deep-ultraviolet laser micro-drilling system (Precision MicroFab) on the outside
surface of the shell (500-1000 µm apart) traversing the shell thickness to generate
Volkmann like microcanals. Microdrilling resulted in the formation of a shell with an
interconnected network of microcanals to stimulate cell migration, vascularization, and
bone formation within the shell wall after implantation.
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Figure 3.1. (a) Natural structure of bone tissue from micron to nano scale. (b) Steps for
fabricating biodegradable, rigid, osteoinductive and osteoconductive shell.

2.2. Characterization of cortical-bone-mimetic scaffolds
The porosity and density of the CaP nucleated NF microsheets before and after heat
treatment were calculated using Eq. (1) and Eq. (2). The thickness and size of the
microsheets were measured using a micrometer caliper (VWR, Atlanta, GA).
Apparent density (mg/mm ) =

Porosity (%) = 1 −

 !""# $

(%)

#!&'" × )*$" $"$ (+ )

/"' #0 *  !""# (%/+ )
/"' #0 * 123 (%/+ )

(1)

(2)

For determination of compressive modulus, the scaffolds were prepared with the
overall thickness of 1 mm and diameter of 1 cm, was loaded on the Peltier plate of an
AR2000 rheometer (TA Instruments, New Castle, DE) and subjected to a uniaxial
compressive force at a displacement rate of 7.5 mm/s. The slope of the linear fit to the
stress–strain curve for 5–10% strain was taken as the elastic modulus (E) of the
mineralized matrix as we previously described
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74

. For determination of mass loss, the

scaffolds were incubated in simulated body fluid (SBF) at 37ºC and under mild agitation.
At each time point, samples were removed from SBF, washed three times with DI water
and dried under vacuum. The dry sample weight was measured and compared with the
initial dry weight to determine the fractional mass remaining as described 75.
3. Results and Discussion
Mineralization in osteons occurs under the function of glutamic-acid rich residues
of bone sialoprotein and osteonectinon on hydroxyapatite nucleation

97, 98

. Therefore,

peptides including polyglutamic acid sequences have been widely investigated to
determine the interaction with nHA crystals. For example, Itoh et al. coated HA with the
synthetic peptide (E7PRGDT), and seeded osteoblastic cells onto the surface. They
demonstrated that the amount of E7PRGDT peptide containing polyglutamic acid
sequence bound to HA was higher than passively adsorbed RGD at all coating
concentrations due to high affinity of polyglutamic acid peptide to nHA crystals

99

. In

addition, Sarvestani et al. treated the surface of nHA particles with glutamic acid peptide
(Ac-Glu6). It was indicated that the average density of elastically active chains in the
PLEOF network increased significantly when nHA in the network were treated with the
osteonectin-derived Ac-Glu6

100

. Similar to others, in our previous study, conjugation of

glutamic acid template peptide on NF significantly increased the CaP nucleation
(Karaman et al. in press). Thus, in this study we used the glutamic acid conjugated NF to
nucleate the CaP crystals. 50 wt% CaP to fiber ratio (GLU-NF/CaP50) was used to
fabricate the osteon-mimetic microtubes. The micro-tubuler structure of the biofabricated
scaffolds ideally mimics the osteons structures of bone tissue 101.
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The effects of the heat treatment on nanofiber microsheets based on CaP to NF
weight ratio porosity and density are shown in Figure 3.2 a and b, respectively. The
results indicated that the porosity of the CaP nucleated microsheets after heating
decreased significantly for all the test groups. In addition, the appeareant density of
different CaP containing GLU-NF microsheets was increased significantly for each test
group after heat treatment.

Figure 3.2. The effect of heat treatment on porosity(a) and density(b) of microsheets

The compressive modulus and strength of the shell was a strong function of the CaP
content of the microsheels (Figures 3.3 a and b). The compressive modulus and strength
of the shell with 240% CaP content were 2.5 GPa and 150 MPa (Figure 3.3 a and b),
respectively, which was in the range of natural compact bone

102, 103

. The degradation of

the engineered shell was inversely related to CaP content (Figure 3.3 c). The shell with
240% CaP content had <5% mass loss after 120 days of incubation in SBF, thus the shell
can potentially provide rigidity during the callus formation stage of bone formation 104.
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Figure 3.3. Compressive modulus (a) and strength (b) of the shell as a function of CaP
content, (c) Mass loss of the shell with incubation time in SBF for CaP contents of 0, 120, 180
and 240%. (d) Magnification of mass remaining results for 120, 180 and 240%.

Also, the compressive modulus of microsheets before and after heat treatment is
compared in Figure 3.3 a. The heat treatment significantly increased the compressive
modulus of the CaP nucleated NF microsheets. For example, the compressive modulus
of 120 wt% CaP microsheets increased from 0.12±0.02 GPa to 1.4±0.2 GPa. And that of
240 wt% increased from 0.26±0.04 GPa to 2.4±0.3 GPa after heat treatment. These
results indicated that the stiffness of microsheets was increased by heat-shrinking the
microsheets. Similar with our results, it has been reported that with the increasing of
apatite amount in nanofibrous microsheets, the tensile modulus of the microsheets
increases significantly 105. In addition, incorporation of nHA crystals in polycaprolactone
fibers increases the tensile modulus of fabricated electrospun NF

106

. Overall, nCaP

deposited NFs have the potential to provide higher structural support to progenitor cells
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compared to NF with no CaP content. It has been observed that increasing mineral
content on NF significantly enhanced MSCs adhesion and differentiation107.
The limitation of nanofibers fabrication with electrospinning is that it produces a
relatively two dimensional fibrous scaffolds. In addition, the pore sizes are relatively
smaller which does not allow cells to penetrate into the scaffold

108

. Therefore, a rigid,

resorbable, and osteoconductive shell with similar microstructure to cortical bone
including interconnected network of microcanals to provide the mechanical stability
needed for large bone fracture was designed in this study. Figure 3.4 shows the SEM
images of different inner diameter microtubes made by 240 wt% CaP coated NF sheets.

Figure 3.4. SEM images of different inner diameter microtubes 250 µm (a), 450 µm (b), and
800 µm (c).

Figure 3.5 shows a hollow center annealed scaffold containg 180 nucleated
microtubes with 240 wt% CaP content. It can be observed in figures 3.5 a and b that this
biofabrication technique results in formation of dens shell-like structure including several
microchannels which mimics that of natural cortical bone (see natural cortical bone
structure in figures 1.2 and 3.1). Additionally, the microholes on the surface of scaffold
can eb clearly seen in figure 3.5 c. The presence of these microholes can be resulted in
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the formation of a shell with an interconnected network of microcanals to stimulate cell
migration, vascularization, and bone formation within the shell wall alter implantation.

Figure 3.5. A cortical bone-mimetic scaffold made by 180 microtubes. (a) Top view of the
cross section of scaffold. (b) Side view of scaffold including the microholes. (c) Magnification of
microholes in the scaffold.

It has been reported that it takes 12 weeks for newly formed callus to become loadbearing as patients

104

undergoing alveolar bone reconstruction wait minimum of 12

weeks for bone to form on the regenerating membrane prior to tooth implantation

109

.

The engineered shell should resorb and transfer load to the newly formed bone to reduce
stress-shielding after 24 weeks 110. The natural dense bone has <15% porosity 111), CaP to
collagen fiber ratio of 200- 300%
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,

compressive modulus and strength of 5 GPa and

90- 170 MPa, respectively 102, 103. Therefore, success is defined by <5% resorption of the
engineered shell after 12 weeks, >75% resorption after 24 weeks, with initial and 1252

weeks compressive strength of 150 MPa and 100 MPa, respectively. The product is an
engineered, rigid, and resorbable shell with interconnected canals to allow vascularization
and bone formation from within the shell wall.
4. Conclusion
In this study, our objective was to investigate the fabrication a 3D formation of
microtubes acffold. The novel aspect of this work is the synthesis of a cortical-bone-mimetic
shell with Haversian-/Volkmann-like canals for nutrient and oxygen supply to the
migrating cells inside the shell. In this aim, aligned, functionalized. nanotmermicrosheets
were nucleated with CaP naocrystals. Then the sheets were wrapped into microtubes, a
set of mierotubes were fused to from a shell. Microhdles were drilled on the shell surface
to form an interconnected network of canals for nutrient and oxygen supply. The shells
will be evaluated with respect tq strength, resorption, and osteogenesis. The target
compressive strength is 150 MPa, mass loss of <5% after 12 weeks and >75% after 24
weeks. Present findings demonstrate that the 3D structure of microrubular scaffolds
provide a promising microenvironment that enhances osteogenesis compared to 2D
microsheet scaffolds.
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CHAPTER 4: FABRICATION OF RESORBABLE, SELF-ASSEMBLED,
POLYETHYLENE GLYCOL BASED NANOGELS FOR CONTROLLED
RELEASE OF GROWTH FACTORS 1
1. Introduction
Bone morphogenetic proteins (BMPs) are the most abundant osteoinductive proteins
which regulate the differentiation and function of cells involved in osteogenesis

112

.

Specifically, it has been proved that BMP-2 is present in different steps of bone healing,
from the initial stages of bone regeneration as well as during later phases including
osteogenesis and chondrogenesis 113, 114. Vascular endothelial growth factor (VEGF) as a
widely used angiogenic growth factor in regenerative medicine plays a key regulatory
role in up-regulation of angiogenesis by signaling vascular endothelial cells to undergo
proliferation, migration, and differentiation into new blood vessels

115

. VEGF's normal

function is to create new blood vessels during embryonic development, new blood
vessels after injury, muscle following exercise, and new vessels (collateral circulation) to
bypass blocked vessels.

1

Barati, D., et al., Spatiotemporal release of BMP-2 and VEGF enhances osteogenic and
vasculogenic differentiation of human mesenchymal stem cells and endothelial colony-forming
cells co-encapsulated in a patterned hydrogel. Controlled Release, 2016. 223: p. 126-136.
Reprinted here with permission of publisher.
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Therefore, an alternative approach like developing biocompatible carriers is
necessary to control both the location and rate of growth factors delivery at the defect
site. PLGA micro- and nanoparticles due to their wide range of degradation times are
used for immobilization and timed-release of BMP2 and VEGF 118-121. However, protein
denaturation by surface adsorption and acidic degradation products of PLGA can
significantly reduce protein bioactivity

122, 123

. Due to the hydrophilicity and chain

flexibility of polyethylene glycol (PEG), PEGylation is used to increase stability of
PLGA nanoparticles in aqueous suspensions, enhance stability of the grafted protein, and
reduce particle phagocytosis

118, 120, 124-126

. In this work, PEG macromers chain-extended

with short lactide (L) and glycolide (G) segments were used to form nanogels (NGs) for
grafting and timed-release of BMP2 and VEGF proteins. In the chain-extended
macromer, the PEG block imparted stability to NGs in aqueous solution, L segment led to
self-assembly and NG formation, and G segment controlled NG degradation and protein
release. We have previously shown that PEG macromers chain-extended with short L/G
segments form micellar structures in aqueous solution

127

. Here, the effect of PEG

molecular weight (MW) and L/G segment length on degradation and protein release
kinetics of the NGs have been investigated.
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Figure 4.1. Synthesis of PEG macromers chain-extended with short lactide (L) and glycolide
(G) segments to form nanogels (NGs) for grafting and timed-release of BMP2 and VEGF proteins

2. Experimental
2.1. Synthesis and functionalization of PEG-LG block copolymer
The PEG-LG block copolymers were synthesized by melt ring-opening
polymerization with successive addition of L and G monomers to the reaction using PEG
as the initiator and TOC as the catalyst. PEG and lactide were added to a reaction flask
equipped with a stirrer and immersed in an oil bath in a molar ratio based on the desired
L segment length (Table 4). Next, the flask was heated to 120°C under nitrogen flow and
maintained at that temperature for 1 h to remove residual moisture. Then, TOC catalyst
was added to the mixture at 120°C and the reaction was allowed to proceed for 6 h at
140°C. The lactide chain-extended PEG macromer was used as an initiator for chain
extension with G monomer with a predetermined L to G ratio (Table 1). The reaction was
allowed to proceed for 6 h at 140°C and the product was precipitated in ice-cold hexane
to remove the unreacted monomers. The synthesized copolymer was functionalized with
succinimide groups by reacting hydroxyl end-groups of the copolymer with DSC as we
described previously

128

. The product was purified by dialysis against DI water and

lyophilized. The chemical structure of the synthesized copolymer was characterized by a
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Varian Mercury-300 1H-NMR (Varian, Palo Alto, CA) as we previously described

129

.

The synthesized macromers are hereafter referred to as PaLGb-Lc (Tables 1 and 2) where
the lowercase letter “a” is the PEG MW in kDa, “b” is LG to PEG molar ratio, and “c” is
the mole fraction of lactide in LG segments. The shorter abbreviations P4-I,II,III, P8I,II,III, and P12-I,II,III stand for those macromers based on 4, 8, and 12 kDa PEG MW,
respectively.
2.2. Nanogel formation and protein grafting
PaLGb-Lc macromer was dissolved in DMSO and self-assembled to form NGs by
dialysis (3.5 kDa MW cutoff) against PBS for 8 h as we previously described

118

. For

BMP2 or VEGF grafting, 10 mg NGs was suspended in 0.5 mL PBS by sonication for 1
min. Next, 0.5 mL of the protein in PBS (20 mg/mL for BSA, 800 ng/mL for BMP2 and
VEGF) was added to the NG suspension. The amine group of the protein was allowed to
react with succinimide end-groups of PaLGb-Lc in NGs under ambient conditions for 12
h as we previously described (Figure 4.1) 119. The protein grafted NGs were freeze-dried
to obtain a free flowing powder. To determine grafting efficiency, the protein grafted
NGs were resuspended in PBS and centrifuged at 18,000 rcf for 10 min and the
supernatant was analyzed for total protein content with the ninhydrin reagent as we
described previously

130

. Grafting efficiency was determined by dividing the amount of

attached protein (total - free protein) by the initial amount in the grafting reaction.
Size distribution of the NGs was measured by dynamic light scattering with a
Submicron Particle Sizer (Model 370, NICOMP, Santa Barbara, CA) as we described
previously

119

. Polydispersity (PD) of the NGs was determined using the equation PD =

∆d/ <d> where ∆d and <d> are the standard deviation and mean size of the NGs,
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respectively

131, 132

. Zeta potential of the NGs was measured with a ZetaPlus analyzer

(Brookhaven Instruments, Holtsville, NY) with a particle concentration of 2.5 mg/mL at
25°C in PBS 133. NGs degradation kinetic was measured by incubation in PBS at 37°C as
we described previously

118

. The fractional mass remaining was determined by dividing

the dried mass at time t by the initial mass. For measurement of release kinetic, 1 mg
protein grafted NGs were incubated in 1 mL PBS at 37°C as we previously described 118.
At each time point, the suspension was centrifuged at 18350 rcf for 10 min, the
supernatant was removed, the NGs were resuspended in 1 mL fresh PBS and incubated
until the next time point. The amount of BSA in the supernatant was measured with the
ninhydrin reagent as described

130

. In the case of BMP2 and VEGF-grafted NGs, the

protein concentration in the supernatant was measured by ELISA as we described
previously 118.
3. Results
3.1. Macromer characterization
The average number of L/G units per PaLGb-Lc was calculated from 1H-NMR
spectra of the macromer. Two chemical shifts with peak positions at 1.6 and 5.2 ppm,
two at 3.6 and 4.2 ppm and one at 4.8 ppm were attributed to the methyl and methine
hydrogens of lactide, the methylene hydrogens of PEG and the methylene hydrogens of
glycolide, respectively

128, 134

. The chemical shift with peak position at 2.77 ppm was

related to the methylene hydrogens of succinimide end-groups. The average segment
length of L and G units per macromer and the number-average MW ( M n ) of the
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macromers are shown in Table 4. The number of L and G units per macromer ranged 2.38.9 and 0.9-5.7, respectively.
3.2. Characterization of nanogels
Size distribution of P4, P8, and P12 NGs and their corresponding SEM images are
shown in Figures 4.3a to c, respectively. In general, mean size of the NGs was <200 nm.
Mean size, PD, and zeta potential of the NGs are given in Table 5. Mean size ranged
from 120±6 to 140±13 nm for P4 NGs, 150±11 to 160±17 nm for P8 NGs, and 170±12 to
190±15 nm for P12 NGs, respectively.

Table 4.1. Number average molecular weight (M_n ) ,̅ LG to PEG feed ratio, average
number of L and G segments per macromer for PaLGb-Lc macromers.

The NGs were relatively monodisperse with PD<0.2 and the mean NG size increased
with decreasing lactide fraction. All NGs were negatively charged with zeta potential
between -23 and -15 mV. The absolute value of the zeta potential increased with
increasing PEG molecular weight while the lactide fraction did not significantly affect
zeta potential.
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Degradation of the NGs with incubation time was biphasic with an initial fast rate
followed by a slow rate (Figure 4.2 a-c). Degradation rate increased with decreasing L:G
ratio for all NGs. Mass loss of P4 and P8 NGs after 24 days incubation increased from
50±5 to 65±3% and 60±8 to 85±2%, respectively, as the L:G ratio decreased from 75:25
to 50:50. P12-I, P12-II and P12-III NGs degraded after 12, 16, and 18 days, respectively.

Table 4.2. Mean size, polydispersity (PD) and zeta potential of NGs formed by PaLGb-Lc
macromers. Error bars correspond to means ± 1 SD for n=3.

P4-I NGs had the slowest degradation with 50±5% mass loss after 30 days and P12III NGs had the fastest degradation with >95% mass loss after 12 days. The release
kinetic of BSA from the NGs in PBS was biphasic with an initial fast rate followed by a
slow rate (Figure 4.3 d-f), consistent with NGs degradation. The release of BSA
increased with decreasing L:G ratio for all NGs. The average BSA release rate of P4, P8,
and P12 NGs increased from 2 to 4.2%/day, 4 to 6.3%/day, and 5.7 to 9.7%/day,
respectively, as L:G ratio decreased from 75:25 to 50:50. P4-I had the slowest BSA
release with 45±8% in 24 days and P12-III had the fastest with >95% released in 12 days.
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Figure 4.2. Effect of PEG MW, LG segment length, and L/G ratio in PaLGb-Lc macromer
on NG mass loss in PBS with incubation time. The abbreviations P4, P8, and P12 represent NGs
made from macromers with PEG MW=4, 8, and 12 kDa and average LG segment length of 8.
The

The extent of bone formation in vivo depends on the duration of BMP2 exposure to
MSCs in the first four weeks 135, 136 whereas vascularization depends on VEGF exposure
to endothelial progenitor cells within the first week 137. Figure 4.3 g represents the release
rate of BMP2 and VEGF encapsulated inside SPELA and GelMA hydrogels,
respectively, compared to BMP2 and VEGF grafted to NGs(21) and NG(10),
respectively. It can be observed that the encapsulated BMP2 and VEGF were completely
released from hydrogels in less than 40 hours while the ones attached to NG(21) and
NG(10) were released steadily after 3 weeks and 7 days, respectively. Therefore, NGs
with steady release for 3 weeks and 71±3 wt% bioactivity (P8-1 NGs) were used for
BMP2 grafting; NGs with steady release for 7 days with 80±5 wt% bioactivity (P12-II
NGs) were used for VEGF (Figure 4.3 g).
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Figure 4.3. Effect of PEG MW, LG segment length, and L/G ratio in PaLGb-Lc macromer
on NG size distribution (a-c), and cumulative BSA release (d-f) in PBS with incubation time.
Release kinetic of BMP2 encapsulated in SEPLA and VEGF encapsulated in GelMA hydrogel
compared to release kinetic of BMP2 grafted to NGs and VEGF grafted to NGs. The
abbreviations P4, P8, and P12 represent NGs made from macromers with PEG MW=4, 8, and 12
kDa and average LG segment length of 8. The abbreviations P4-I, P4-II, and P4-III represent NGs
made from 4 kDa MW PEG macromers with 75%, 60%, and 50% lactide in the LG segments,
respectively. The numbers in abbreviations NG(21) and NG(10) represent the release time of
grafted proteins on each type of NG. Morphology of the dried NGs is shown in the inset SEM
images in (a-c). Error bars correspond to means ± 1 SD for n=3.

4. Discussion
Size distribution of nanoparticles self-assembled from PEG-LG macromers depends
on the rate of particle assembly which in turn is related to the length of hydrophobic LG
segments 138. We previously generated nanoparticles (NPs) by self-assembly of ultra-low
molecular weight ULMW-PLGA (1-2 kDa MW) with amphiphilic copolymers of PEG
(3.4 kDa) and ULMW-PLA (PLEOF). The resulting NPs had mean sizes in the 200-300
nm range and relatively wide size distributions from 100 to 600 nm 118. In this work, we
used a different approach to generate PEG-LG macromers by extension of PEG chainends with a short L segment followed with a short G segment. The average length of the
L segments was 5-10 (Table 4, note two ends per chain) while it was 15-30 in the
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previous approach with ULMW-PLAF/PLEOF

118

. The relatively shorter hydrophobic

segments in PaLGb-Lc led to the formation of hydrophilic NGs with mean sizes as low as
120 nm and size distributions as narrow as 25-150 nm. The more hydrophobic L segment
in PaLGb-Lc controlled NGs assembly whereas the less hydrophobic G segment
controlled NGs degradation.
As the PEG MW was increased from 4 to 8 and 12 kDa in P4-I, P8-I and P12-I,
the L segment length had to be increased from 2.3 to 3.8 and 5.4, respectively, to induce
self-assembly for the macromer with 50/50 L/G ratio (Table 4). As the L segment length
in P4-I, P8-I and P12-I increased, mean NG size increased from 118±6 nm to 141±11 and
165±12 nm (Table 3), respectively. Length of the PEG block regulated the extent of
association between the macromers by balancing van der Waals and dipolar interactions
to prevent aggregation of hydrophobic LG segments 139. The measured NG sizes in Table
5 are consistent with the previously reported increase in the average diameter of PLAPEG nanoparticles from 30 to 60 nm with increasing PLA block MW from 3 to 30 kDa
140

. The measured zeta potentials of the NGs (-15 to -22 mv) was significantly less than

the reported values for PLA or PLGA nanoparticles (~ -50 mv)

141

which was attributed

to the negatively-charged carboxyl end-groups of PEG and their higher fraction in the
NGs corona at higher PEG MWs 139.
It has been shown by us and others that the degradation kinetic of PEG-LG based
micelles depends on the proximity of water molecules to L and G ester groups

127, 142

which is dependent on PEG MW and hydrophobicity of the degradable units

143, 144

,
.

Consequently, PEG MW had the greatest effect on NGs degradation followed by the
fraction of less hydrophobic G in LG segments (Figure 4.3 d-f). Release kinetic of BSA
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grafted to the NGs followed the degradation of NGs (Figure 4.3 g-i). P4-III, P8-III, and
P12-III NGs (50% G) with PEG MW of 4, 8, and 12 kDa lost 52, 61, and 94% mass after
12 days, respectively; those NGs released 67, 78, and 95% of the grafted BSA after 12
days. P8-I, P8-II, and P8-III NGs ( (PEG MW 8kDa) with 25, 40, and 50% G in LG
segments lost 30, 41, and 61% mass after 12 days incubation, respectively, those NGs
released 58%, 62%, and 78% of the grafted BSA after 12 days.
5. Conclusion
Fabrication and characterization of resorbable NGs based on self-assembly of PEG
macromers chain-extended with short L and G segments were investigated. It was shown
that the NGs properties can be controlled by changing the molecular weight of PEG and
ratio of L to G. For example, it was observed that degradation rate and protein release of
the NGs increased with decreasing L to G ratio for the same PEG molecular weight.
Therefore, these NGs can be potentially used as a carrier for temporal controlled release
of different types of growth factors for different purposes.
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CHAPTER 5: EVALUATING THE EXTENT OF VASCULOGENESIS AND
OSTEOGENESIS STEM CELLS ENCAPSULATED IN A PATTERNED
HYDROGEL WITH SPATIOTEMPORAL RELEASE OF BMP2 AND VEGF.
1. Introduction
The reconstruction of large bone defects with implanted scaffolds due to resection of
tumors, skeletal trauma, or infection remains a significant clinical problem

145

. The high

clinical failure rates with allografts and implanted scaffolds are attributed to insufficient
vascularization and slow bone regeneration

146

. Engineered matrices that can guide

concerted differentiation of multiple cell types to both vasculogenic and osteogenic
lineages are promising for the treatment of large bone defects. In that regard, natural and
synthetic matrices loaded with bone morphogenetic proteins (BMPs), with or without
mesenchymal stem cells (MSCs), have been used extensively as a graft to accelerate bone
repair and healing

147

. Among BMPs, recombinant human BMP-2 (hereafter referred to

as BMP2) is used as a potent osteogenic factor in certain clinical applications including
spine fusion and alveolar ridge augmentation

148

. Similarly, the widely used vascular

endothelial growth factor (VEGF) is not only involved in angiogenesis, but also
implicated in maturation of osteoblasts, ossification, and bone turnover

115, 149

bioactivity of BMP2 and VEGF is concentration and time-dependent

. As the

135-137

sustained delivery from biodegradable particulate systems has been investigated
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, their

118, 120 .

Osteogenesis and vascularization during bone development and growth are coupled
processes

149, 153

. VEGF plays a key role in blood vessel invasion into hypertrophic

cartilage as the endothelial cells in the invading vessels secrete growth factors that
stimulate osteogenesis

149, 154

. There is a close correlation between vascularization and

bone formation in endochondral ossification as maximum extent of bone formation
follows maximum levels of VEGF expression

155

. In the bone marrow, endothelial

progenitor cells form an osteoblast-vascular niche by close proximity to osteoprogenitor
cells in the endosteum

156

. Hence, several studies have investigated the combined effect

of BMP2 and VEGF on osteogenic and vasculogenic differentiation of MSCs and
endothelial progenitor cells (EPCs).

Figure 5.1. Vasculogenesis and osteogenesis are tightly coupled processes during bone
formation

In one study

157

, the extent of osteogenic differentiation of rat MSCs co-expressing

BMP2 and VEGF in 2D culture was lower than MSCs expressing only BMP2. In another

66

study

158

, in which MSCs in combination with EPCs were seeded in a calcium

sulfate/alginate scaffold, the extent of osteogenic and vasculogenic differentiation of
MSC+EPC group in vitro and in vivo (bone formation and blood vessel density) was
significantly higher than the groups with only MSCs or EPCs. Furthermore in that study,
the MSC+EPC group had higher extent of mineralization and vascularization than the
group with BMP2-expressing MSCs. These previous studies indicate that EPCs not only
take part in vascularization but they also enhance osteogenesis in combination with
MSCs 159.
There is conflicting reports on the effect of VEGF and its combination with BMP2
on the extent of bone formation in vivo

160-162

. In an in vivo study

161

, BMP2-expressing

MSCs in combination with VEGF-expressing EPCs encapsulated in an alginate gel
showed higher extent of bone formation after intramuscular implantation compared to the
alginate gel with MSCs and VEGF-expressing EPCs. Further, VEGF-expressing EPCs
hindered terminal differentiation of MSCs in co-cultures of EPCs+MSCs 161. In an in vivo
study in rat cranium

162

, dual delivery of BMP2 and VEGF from gelatin nanoparticles

embedded in a porous scaffold increased bone formation after 4 weeks implantation, but
not after 12 weeks, compared to the delivery of BMP2 only. In addition, in an in vivo
study in canine ulna

160

, the extent of bone formation in a calcium phosphate scaffold,

embedded with BMP2 and VEGF in poly(lactide-co-glycolide) (PLGA) nanoparticles,
was independent of VEGF. Also, in an in vivo study in rat, dual delivery of VEGF from a
gelatin hydrogel surrounding a solid matrix embedded with BMP2-encapsulated PLGA
microspheres had no effect on bone formation in an orthotopic site compared to BMP2
alone

163

. However, dual and sustained delivery of BMP2 and VEGF enhanced bone
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formation in an ectopic site

163

where MSCs and EPCs can potentially migrate from the

surrounding tissue to the site of regeneration.
The previous studies suggest that dual BMP2 and VEGF delivery is effective in the
presence of both MSCs and EPCs. Further, the addition of VEGF seems to retard
maturation of MSCs to osteoblasts. This suggests that osteogenesis and vascularization
may be coupled by spatiotemporal regulation of paracrine signaling in which the invading
vascular endothelial cells secrete osteogenic morphogens to stimulate MSC
differentiation and bone formation 164.

Figure 5.2. Dual delivery of BMP2 and VEGF in 21 and 10 days, respectively.

We hypothesized that osteogenesis and vascularization are coupled by the spatial and
temporal expression of morphogens secreted by the differentiating MSCs and invading
vascular endothelial cells. In this work, we test the hypothesis in vitro with human MSCs
(hMSCs) and human colony-forming endothelial cells (ECFCs) encapsulated in a
patterned hydrogel with spatiotemporal release of BMP2 and VEGF. Microchannels were
generated in lactide-chain-extended star polyethylene glycol (SPELA) hydrogel. hMSCs
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and BMP2-grafted NGs (BMP2-NGs) were encapsulated in the SPELA hydrogel. The
microchannels were injected with a suspension of ECFCs+hMSCs and VEGF-grafted
NGs (VEGF-NGs) in gelatin methacryloyl (GelMA) and crosslinked. The hydrogel
constructs were cultured in vasculogenic/osteogenic medium (without VEGF or BMP2)
and characterized with respect to the extent of osteogenic/vasculogenic differentiation of
hMSCs and ECFCs.

Figure 5.3. (a) Schematic diagram for NG assembly and protein grafting. The diagram is for
illustration of protein grafting to NGS and is not intended to show the actual nanostructure of the
NGs. (b) Schematic diagram of vasculogenic GelMA microchannels in osteogenic SPELA gel for
patterned constructs. The SPELA precursor solution loaded with hMSCs and NG-BMP2 was
injected inside a Teflon cylinder (5 mm diameter and 3 mm height) fitted with 12 needles spaced
500 µm apart. After gelation, the needles were removed and the GelMA precursor solution loaded
with ECFCs+hMSCs and NG-VEGF was injected in the microchannels and UV crosslinked.
After gelation, the cell-encapsulated construct was incubated in vasculogenic medium (without
VEGF) for the first week, 50:50 mixture of vasculogenic and osteogenic medium (without VEGF,
BMP2, and DEX) for three days (days 8-10), and finally in osteogenic medium (without DEX
and BMP2, days 11-21).
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2. Experimental
2.1. Encapsulation and differentiation of hMSCs and ECFCs in the un-patterned
constructs
For the un-pattarned osteogenic constructs, hMSCs and BMP2-NGs were
encapsulated in SPELA hydrogel and cultured in osteogenic medium without DEX and
BMP2 (basal medium plus 50 µg/mL AA and 10 mM βGP). Osteogenic constructs
included hMSCs in SPELA gel without BMP2, with dissolved BMP2, and BMP2-NGs.
Briefly, 20 mg of BMP2-NGs (1.2 µg BMP2) were suspended in 1 mL of SPELA gel
precursor solution [200 mg SEPLA macromer, 4 mg Ac-GRGD (2 wt% of macromer) for
cell adhesion, and 7.5 mg (0.75 wt%) photo-initiator (Irgacure-2959, CIBA)] and the
suspension was sterilized by filtration. Next, hMSCs at a density of 2x106 cells/mL were
suspended in the sterile SPELA precursor solution, injected between two sterile glass
slides, and crosslinked by exposure to UV irradiation as we previously described 134. For
the un-patterned vasculogenic constructs, a 50:50 mixture of hMSCs+ECFCs

134

plus

VEGF-NGs was encapsulated in GelMA hydrogel and cultured in EMB-2 BulletKit
medium (Lonza) without the addition of VEGF. Vasculogenic constructs included
hMSCs+ECFCs in GelMA hydrogel without VEGF, with dissolved VEGF, and VEGFNGs. Briefly, 2 mg VEGF-NGs (120 ng VEGF) was suspended in 1 mL of GelMA
precursor solution (50 mg GelMA and 7.5 mg photo-initiator) and sterilized. Next, 50:50
mixture of hMSCs+ECFCs at a total density of 2x106 cells/mL was suspended in the
sterile GelMA precursor solution, injected between glass slides, and crosslinked by UV
irradiation as described

134

. After gelation, disk-shape gels (7 mm diameter and 0.5 mm

thickness) were cut and incubated in PBS for 1 h with two PBS changes. Next, the media
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was replaced with osteogenic (without DEX and BMP2) or vasculogenic (without VEGF)
medium and incubated for 21 and 10 days, respectively.
2.2. Encapsulation and differentiation of hMSCs and ECFCs in the patterned
constructs
Patterned hydrogels with GelMA micro-channels in a SPELA matrix were generated
for osteogenic-vasculogenic co-culture experiments. Twelve 900-µm diameter needles
(G-20) were inserted through the end-caps of a Teflon cylinder with diameter and height
of 5 and 3 mm, respectively. The distance between the needles was 500 µm. Next, the
sterile SPELA precursor solution (200 mg SPELA macromer, 4 mg Ac-GRGD, 7.5 mg
photo-initiator, 20 mg BMP2-NGs, and 2x106 hMSCs in 1 mL PBS) was injected
between the needles and crosslinked with UV as described (Figure 5.3 b)

134

. Then, the

needles were removed and the GelMA precursor solution (50 mg GelMA, 7.5 mg photoinitiator, 2 mg VEGF-NGs, and 2x106 hMSCs/ECFCs in 1 mL PBS) were injected in the
channels and crosslinked with UV as described (Figure 5.3 b)

134

. After gelation, the

patterned constructs were washed with PBS and incubated in vasculogenic medium
(without VEGF) for the first week, 50:50 mixture of vasculogenic and osteogenic
medium (without VEGF, BMP2, and DEX) for the next three days (days 8 -10), and
finally in osteogenic medium (without DEX and BMP2) for 11 days (days 11-21).
Experimental groups included patterned constructs without BMP2/VEGF, BMP2
dissolved in SPELA gel plus VEGF in GelMA, and BMP2-NGs in SPELA gel plus
VEGF-NGs in GelMA.
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2.3. Characterization of cells behavior encapsulated in patterned and un-patterned
hydrogels
Biochemical, mRNA, and protein analysis, alizarin red and Immunofluorescent
staining techniques were used to characterized the extent of osteogenesis and
vasculogenesis of cells in hydrogels.
3. Results
3.1. Osteogenic differentiation of hMSCs and ECFCs encapsulated in patterned
hydrogels with BMP2 and VEGF NGs
DNA content, ALP activity, calcium content, and mRNA expression of osteogenic
markers for ECFCs+hMSCs/NG-VEGF encapsulated in GelMA channels and
hMSCs/NG-BMP2 encapsulated in SPELA matrix in the patterned constructs are shown
in Figure 5.4 (blue curve). Controls included ECFCs+hMSCs in the channels and hMSCs
in the matrix with (red curve, without NG grafting) and without (green curve) VEGF and
BMP2 in the channels and matrix, respectively. Other controls included hMSCs/BMP2
(dashed pink) and hMSCs/NG-BMP2 (dashed light blue) in SPELA gel (no GelMA
channels) and cultured in osteogenic medium (without DEX and BMP2) for 21 days.
DNA content of the groups with BMP2/VEGF (with or without NG grafting) decreased
significantly with time which was related to the differentiation of encapsulated cells, as
we previously described

165

(Figure 5.4 a). ALP activity of hMSCs in un-patterned

osteogenic constructs with BMP2 or BMP2-NGs (dashed curves) increased significantly
from day 7 to 14, reached a maximum after 14 days and decreased from day 14 to 21
(Figure 5.4 b). The peak ALP activity of hMSCs in the patterned constructs with
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BMP2/VEGF (with or without grafting) was delayed to day 18 because the constructs
were cultured in vasculogenic medium in the first 7 days (Figure 5.4 b). The patterned
constructs (solid lines) had higher ALP activity than their corresponding un-patterned
osteogenic constructs (dashed lines). The patterned constructs with NG-BMP2/NGVEGF (blue curve) and without BMP2/VEGF (green curve) had the highest and lowest
ALP activity with 6100±500 and 2000±300 IU/mg DNA, respectively. Calcium content
as a measure of the extent of mineralization for all groups steadily increased with
incubation time (Figure 5.4 c). After 21 days incubation, the patterned constructs (solid
lines) had higher calcium content than their corresponding un-patterned osteogenic
constructs (dashed lines). The patterned constructs with NG-BMP2/NG-VEGF (blue
curve) and without BMP2/VEGF (green curve) had the highest and lowest calcium
content after 21 days with 710±50 and 220±30 mg/mg DNA, respectively (Figure 5.4 c).
mRNA expression of RUNX2 transcription factor initially increased with incubation
time for all groups, peaked at day 14, and then decreased. The un-patterned osteogenic
construct with NG-BMP2 and the patterned construct with NG-BMP2/NG-VEGF had the
highest RUNX2 expression while the patterned construct without BMP2/VEGF had the
lowest RUNX2 expression (Figure 5.4 d). Interestingly, RUNX2 expression of the
patterned construct with NG-BMP2/NG-VEGF decreased slightly with incubation after
day 14 (Figure 5.4 d). mRNA expression of ALP (Figure 5.4 e) followed a trend similar
to that of ALP activity shown in Figure 5.4 b.
The patterned construct with NG-BMP2/NG-VEGF (blue curve) had highest ALP
expression at day 14. mRNA expression for Col I for all groups increased steadily with
incubation time (Figure 5.4 f). The un-patterned osteogenic construct with NG-BMP2
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and the patterned construct with NG-BMP2/NG-VEGF had the highest Col I expression
after 21 days incubation.

Figure 5.4. DNA content (a), ALP activity (b), calcium content (c), and mRNA expression of
osteogenic markers Runx2 (d), ALP (e), and Col I (f) for hMSCs and ECFCs in the patterned
constructs. Groups included patterned constructs without VEGF/BMP2 (green), with
VEGF/BMP2 (red), and with NG-VEGF/NG-BMP2 (blue); un-patterned constructs with NGBMP2 (dashed light blue) and with BMP2 (dashed pink). Patterned constructs were incubated in
vasculogenic medium for 7 days, vasculogenic/osteogenic medium for 3 days, and osteogenic
medium for 11 days (without VEGF, BMP2, and DEX). Un-patterned constructs were incubated
in osteogenic medium without DEX and BMP2 for 21 days. (e) Alizarin red stained (dark red)
images of the patterned constructs along the length of a microchannel with none, dissolved, and
NG-grafted BMP2/VEGF after 4 and 21 days of incubation. BMP2 and VEGF in NG-VEGF/NGBMP2 group have 21 days and 10 days release, respectively.One star indicates statistically
significant difference (s.d.; p<0.05) between the test group and None (green); two stars between
the test group and BMP2/VEGF (red). Error bars correspond to means ± 1 SD for n=3.

The images in Figure 5.4g show Alizarin red staining along the length of a
microchannel for the patterned constructs with none, dissolved, and NG-grafted
BMP2/VEGF after 4 and 21 days of incubation. The image for patterned construct with
NG-grafted BMP2/VEGF after 21 days (bottom right image) showed significantly higher
staining in the matrix (dark red) and lower staining in the channels compared to the other
groups.
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3.2. Vasculogenic differentiation of hMSCs and ECFCs encapsulated in patterned
hydrogels with BMP2 and VEGF NGs
DNA content, CD31 protein, and mRNA expression of vasculogenic markers for
ECFCs+hMSCs/NG‐VEGF encapsulated in GelMA channels and hMSCs/NG‐BMP2
encapsulated in SPELA matrix in the patterned constructs are shown in Figure 5.5 (blue
curve). Controls included ECFCs+hMSCs in the channels and hMSCs in the matrix with
(red curve, without NG grafting) and without (green curve) VEGF and BMP2 in the
channels and matrix, respectively. Other controls included ECFCs+hMSCs/VEGF
(dashed pink) and ECFCs+hMSCs/NG‐VEGF (dashed light blue) in GelMA (no SPELA)
and cultured in vasculogenic medium (without VEGF) for 21 days. DNA content of the
groups with BMP2/VEGF (with or without NG grafting) decreased with time with
differentiation of the encapsulated cells

134

(Figure 5.5 a). CD31 protein expression for

the patterned construct without BMP2/VEGF (green curve) did not increase significantly
with time (Figure 5.5 b,c). CD31 expression of the un-patterned vasculogenic constructs
with VEGF (dashed pink) or NG-VEGF (dashed light blue) increased with time but the
CD31 expression for the NG-VEGF construct was significantly higher than that of VEGF
(Figure 5.5 b,c). The patterned constructs (solid lines) had higher CD31 expression than
the un-patterned vasculogenic constructs (dashed lines) for all incubation times. For
example after 10 days of incubation, CD31 expressions for patterned constructs with NGBMP2/NG-VEGF and BMP2/VEGF were 0.91±0.08 and 0.75±0.12, respectively; the
expressions for the un-patterned vasculogenic constructs were 0.78±0.12 and 0.52±0.07.
For all time points, CD31 expression of patterned construct with NG-BMP2/NG-VEGF
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was higher than the other groups. mRNA expressions of vWF, CD31, and VE-cadherin
(Figure 5.5 d-f) with incubation time were consistent with the CD31 protein expression in
Figure 5.5 b. The patterned construct with NG-BMP2/NG-VEGF (blue curve) had higher
expression of vWF, CD31, and VE-cadherin than the other groups for all time points.

Figure 5.5. DNA content (a), CD31protein expression (b), representative western blot bands
(c), and mRNA expression of vasculogenic markers vWF (d), CD31 (e), and VE-cadherin (f) for
hMSCs and ECFCs in the patterned constructs (see Figure 5.4 for the groups). (e) CD31 stained
(green) images of the patterned constructs along the length of a microchannel with none,
dissolved, and NG-grafted BMP2/VEGF after 4 and 10 days of incubation. BMP2 and VEGF in
NG-VEGF/NG-BMP2 group have 21 days and 10 days release, respectively. One star indicates
statistically significant difference (s.d.; p<0.05) between the test group and None (green); two
stars between the test group and BMP2/VEGF (red). Error bars correspond to means ± 1 SD for
n=3.

The images in Figure 5.5 g show CD31 staining (green) along the length of a
microchannel for the patterned constructs with none, dissolved, and NG-grafted
BMP2/VEGF after 4 and 10 days of incubation. The image for patterned construct with
NG-grafted BMP2/VEGF after 10 days (bottom right image) showed significantly higher
CD31 expression in the channel compared to the other groups.
bFGF protein expression of the un-patterned osteogenic, patterned, and un-patterned
vasculogenic constructs are shown in Figures 5.6 a-c, respectively. For a given time
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point, patterned constructs and the un-patterned osteogenic constructs had highest and
lowest expression of bFGF, respectively, with or without protein grafting. For a given
culture system, the groups with grafted proteins had the highest expression of bFGF after
14 and 21 days of incubation. Overall, the patterned construct with NG-BMP2/NGVEGF had highest expression of bFGF after 14 and 21 days among all groups (Figure 5.6
b). For example, bFGF expression of the patterned construct with none, dissolved, and
NG-grafted BMP2/VEGF after 21 days incubation was 160±7, 54±4, and 23±1 ng/mL,
respectively (Figure 5.6 b); those of the un-patterned vasculogenic constructs was
110±12, 48±4, and 19±5 ng/mL (Figure 5.6 c); and those of the un-patterned osteogenic
constructs was 49±7, 14±4, and zero ng/mL (Figure 5.6 a). In addition, the effect BMP2
and VEGF release rate in patterned constructs on bFGF protein expression has been
shown in figure 5.6.
The groups with 21 days release of BMP2 and 10 days release of VEGF (dashed blue
curve) had the highest bFGF expression compared to the other two groups with 10 days
or 21 days release for both BMP2 and VEGF (dashed green and red curves) with 149±9
and 120±6 ng/ml bFGF expression, respectively, after 21 days.It should be mentioned
that there was no significant difference between the bFGF expression of NG(21)BMP2/NG(10)-VEGF and NG(10)-BMP2/NG(10)-VEGF groups.
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Figure 5.6. bFGF protein expression of the un-patterned osteogenic (a), patterned (b), and
un-patterned vasculogenic (c) constructs with incubation time for the groups with none,
VEGF/BMP2, and NG(21)-BMP2/NG(10)-VEGF. (d) Effect of BMP2 and VEGF release rate on
bFGF protein expression of patterned construct. Groups included patterned constructs without
VEGF/BMP2 (green, c), with VEGF/BMP2 (red, c), and with NG(21)-BMP2/NG(10)-VEGF
(blue, b); un-patterned osteogenic constructs with NG(21)-BMP2 (light blue, a) and with BMP2
(pink, a); and un-patterned vasculogenic constructs with NG(10)-VEGF (dashed light blue in b)
and with VEGF (dashed pink in b). Groups with NG(21)-BMP2/NG(10)-VEGF (dashed blue in
d), NG(21)-BMP2/NG(21)-VEGF (dashed red in d) and NG(10)-BMP2/NG(10)-VEGF (dashed
green in d) shows patterned construct with different protein release rate. The numbers in
abbreviations NG(21) and NG(10) represent the release time of grafted proteins on each type of
NG. One star indicates statistically significant difference (s.d.; p<0.05) between the test group
and None (green); two stars between the test group and BMP2 (pink in a) or VEGF (dashed pink
in b) or BMP2/VEGF (red in c) or NG(21)-BMP2/NG(21)-VEGF (dashed red in d). Error bars
correspond to means ± 1 SD for n=3.

4. Discussion
It has been reported that the extent of bone formation in vivo depends on the duration
of BMP2 exposure to MSCs in the first four weeks

135, 136

whereas vascularization

depends on VEGF exposure to endothelial progenitor cells within the first week

137

.

Therefore, P8-I NGs with 90% BSA release in 24 days and P12-II NGs with 70% BSA
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release in 7 days were used for timed release of BMP2 and VEGF in the osteogenic
SPELA matrix and vasculogenic GelMA channels, respectively. 78% and 71% of the
grafted VEGF and BMP2 proteins, respectively, were released at a constant rate for 7 and
21 days, without an initial burst release

150

, in the enzymatically-active conformation.

Comparison of BSA (70 kDa) release curves with those of VEGF (40 kDa) and BMP2
(26 kDa) indicated that the protein release was dominated by the NGs degradation. PLGA
and heparin-functionalized PLGA nanoparticles have previously been used for BMP2
delivery and gelatin microparticles have been used for VEGF. Attachment of BMP2 to
heparin-functionalized PLGA (90 kDa) nanoparticles and their encapsulation in a fibrin
gel prolonged the release to 2 weeks, but the fraction of bioactive BMP2 released was
23% compared to 57% for untreated PLGA nanoparticles

121

. Encapsulation in gelatin

microspheres prolonged VEGF release to 2 weeks but <45% of the protein was released
from the microparticles 150. In another study, the fraction of bioactive BSA released from
PLGA (45 kDa) nanoparticles increased from 50% to 70% after 1 week incubation by
copolymerization of PLGA with PEG (5 kDa) 120. We previously reported that the release
of BMP2 can be extended to 4 weeks by grafting to succinimide-functionalized blend of
ULMW-PLA/PLEOF nanoparticles but <50% of the released protein was enzymatically
active

118

. Release kinetic of VEGF and BMP2 from PaLGb-Lc NGs (Figure 4.3 g)

suggests that hydrophilic NGs are a more efficient platform for grafting and timed-release
of proteins than hydrophobic PLGA nanoparticles. The lower bioactivity of BMP2
released from PLGA nanoparticles could be attributed to protein denaturation by acidic
degradation products of PLGA and protein adsorption/unfolding 122.
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Several recent studies have investigated the combined effect of VEGF and BMP2 on
osteogenesis and vascularization

157, 158, 160-162

. Based on previous experimental results,

co-expression of BMP2 and VEGF in MSC cultures had no effect on the extent of
mineralization in vitro. On the other hand, combination of MSCs and EPCs in a calcium
sulfate scaffold without over-expression of BMP2 showed higher mineralization in vitro
compared to BMP2-expressing MSC only group

158

. Dual delivery of VEGF and BMP2

in vivo increased bone formation only at early time points but it was relatively
independent of VEGF at late time points

160, 162, 163

. In another study, combination of

BMP2-expressing MSCs and VEGF-expressing EPCs in a scaffold significantly
increased bone formation after intramuscular implantion in rat

161

. The previous results

indicate that dual delivery of BMP2 and VEGF increases osteogenesis only in MSC and
EPC co-cultures. Our results in Figures 5.4 and 5.5 demonstrate that localized, dual
delivery of VEGF to ECFCs+hMSCs in the channels and BMP2 to hMSCs in the matrix
significantly increased the extent of mineralization and vascularization. Further, localized
timed-release of VEGF in the channels and BMP2 in the matrix by grafting to NGs
significantly improved mineralization and vascularization (blue curves in Figures 5.4-5.5)
compared to direct addition of growth factors (red curves in Figures 5.4-5.5).
These results suggest that differentiation and maturation of MSCs and ECFCs to
osteoblasts and endothelial cells induced by BMP2 and VEGF, respectively, may be
indirectly coupled; that is differentiation of ECFCs+hMSCs in the channels by VEGF
leads to the release of osteogenic factors that diffuse to the matrix to stimulate
osteogenesis. bFGF is shown to mediate vascularization and bone formation in MSC
seeded scaffolds

166, 167

. Therefore, we measured the expression of bFGF at the protein
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level for the un-patterned and patterned constructs (Figure 5.6). The un-patterned
vasculogenic construct without VEGF expressed low levels of bFGF after 7 and 10 days
incubation (green in c) whereas the un-patterned osteogenic construct without BMP2 did
not express bFGF in 21 days (green in a). The un-patterned vasculogenic construct with
VEGF (dashed pink and blue in c) had higher expression of bFGF than the un-patterned
osteogenic construct with BMP2 (dashed pink and blue in a). bFGF expression of the
patterned construct with direct addition of BMP2/VEGF (red in b) was comparable to
those of un-patterned vasculogenic construct with VEGF (dashed pink in c). Overall,
timed-release of NG grafted BMP2/VEGF significantly enhanced bFGF expression level
in un-patterned (dashed pink in a,c) and patterned (blue in b) constructs. However, timedrelease of BMP2/VEGF in the patterned construct sharply increased bFGF expression
level after 14 and 21 days (blue in b) compared to direct addition of the growth factors
(red in b). The results with NG-BMP2/NG-VEGF support previous reports on the effect
of timed-release of VEGF and BMP2 on vascularization and osteogenesis, respectively
168-170

.

During endochondral ossification, maximum levels of VEGF precede maximum
levels of new bone formation

155

. In the mineralization front, differentiated vascular

endothelial cells in the invading vessels secrete growth factors that stimulate
differentiation of MSCs to the osteogenic lineage 149. Consistent with the process of bone
development in vivo, bFGF expression levels in Figure 5.6 suggests that the differentiated
ECFCs+hMSCs in the channels secret bFGF, and possibly other growth factors, that
synergistically enhance osteogenic differentiation of hMSCs and mineralization. The data
in Figure 5.6 also indicates that timed-release of NG-grafted VEGF in the channels leads
81

to sustained production of bFGF in the first week of co-culture to stimulate maturation of
the differentiated cells to osteoblasts and endothelial cells.
5. Conclusion
We investigated the effect of spatial and temporal release of BMP2 and VEGF on the
extent of osteogenic and vasculogenic differentiation of hMSCs and ECFCs encapsulated
in a patterned hydrogel. For timed-release, BMP2 and VEGF were grafted to resorbable
NGs based on self-assembly of PEG macromers chain-extended with short L and G
segments. Degradation rate and protein release of the NGs increased with decreasing L to
G ratio. Based on NGs release profile, P12-II NGs with 12 kDa PEG MW, 12 LG
segment length, and 60/40 L/G ratio was selected for VEGF grafting and release in 7
days. P8-I NGs with 8 kDa PEG MW, 13 LG segment length, and 60/40 L/G ratio was
selected for BMP2 grafting and release in 21 days. Enzymatic activity of the released
VEGF and BMP2 after 7 and 21 days was 80% and 71%, respectively. hMSCs and
ECFCs were encapsulated in patterned hydrogels with NG-grafted proteins; that is,
hMSCs and BMP2-NGs encapsulated in SPELA matrix and hMSCs+ECFCs and VEGFNGs in GelMA microchannels. Control groups were hMSCs in the un-patterned SPELA
and hMSCs/ECFCs in the un-patterned GelMA. Based on the results, the extent of
osteogenic and vasculogenic differentiation of hMSCs and ECFCs was higher in
patterned constructs compared to un-patterned constructs. The addition of VEGF-NGs in
the channels and BMP2-NGs to the matrix significantly increased osteogenic and
vasculogenic differentiation of hMSCs and ECFCs compared to the addition of VEGF
and BMP2. The patterned constructs with timed-release of NG-grafted VEGF and BMP2
had highest extent of osteogenic and vasculogenic differentiation. Further, timed-release
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of NG-grafted VEGF in hMSC+ECFC seeded channels and NG-grafted BMP2 in hMSCseeded matrix sharply increased bFGF expression after 21 days in the co-cultured
constructs. The results suggest that mineralization and vascularization may be coupled by
localized secretion of paracrine signaling factors like bFGF by differentiating hMSCs and
ECFCs.
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CHAPTER 6: FUTURE WORK
Traditional attempts to grow bone grafts in the laboratory were based on culturing
cell/scaffold constructs under static conditions in the presence of osteogenesis-inducing
factors. However, static cultures are not optimal to grow centimeter-sized bone grafts for
clinical translation due to poor nutrient supply and removal of metabolic waste. Under
these conditions, in fact, mass transport occurs only via diffusion, which is not sufficient
to support cell survival and proliferation inside the core of large cell/scaffold constructs,
resulting in necrosis and poor tissue formation. In addition, cell proliferation and matrix
synthesis at the construct periphery over the culture period further impede medium
diffusion and contribute to the formation of a nutrient gradient that drive cell migration
towards the substitute borders

171

. On top of this, culture in static conditions does not

allow provision of those biophysical stimuli that are critical for functional regeneration
172, 173

. In fact, bone cells are sensitive to mechanical stimuli, whose integration and

conversion into intracellular signals play an important role in driving bone remodeling
throughout lifetime and regeneration during fracture healing

174, 175

. Human bone is

principally subjected to two types of mechanical stimuli, i.e., strain caused by
deformation (bending and compression) resulting from physical activity (estimated
values <2000 µε), and fluid shear stress resulting from interstitial fluid movement
through the lacunae as a consequence of loading (estimated values 0.8–3 Pa)

84

176

.

Conversion of physical stimuli into molecular signals and biological responses is
termed mechanotransduction, which principally relies on the regulation of stretchactivated ion channels and integrin-initiated cytoskeleton deformations and organelle
displacement 177 that ultimately triggers the initiation of a cascade of events culminating
in the activation of genes involved in osteogenic pathways

176

. Based on this knowledge,

it is clear that the recapitulation of these mechanisms in vitro is essential for fostering the
regenerative properties of human osteocompetent cells seeded onto biomaterial scaffolds,
thus enabling the formation of mature tissue substitutes for enhanced skeletal
reconstructions. Advances in bioreactor systems over the last two decades have opened
new possibilities in the field of bone engineering as they allow to nurture the
development of bone tissue by providing an appropriate physiological environment with
stimulatory biochemical and biophysical signals

178

. The combination of stem cells,

biomaterials, osteogenesis-inducing factors and bioreactor systems has recently been
defined as the “Tissue Engineering Quadriad”

179

, with the culture under dynamic

conditions representing a paradigm shift for the ex vivo construction of viable tissue
substitutes for replacement and reconstructive therapies. Not least, the construction of
viable bone substitutes using bioreactor systems opens new opportunities for the
generation of valid experimental models to study bone development and pathologies,
screen new drugs and test biomaterials within a context that better reflects the native
tissue environment. Therefore, the first step in the future would be evaluating the extent
of osteogenesis and vasculogenesis of stem cells in the engineered shell-core composite
with timed and localized delivery of BMP2 and VEGF with respect to mineralization and
vascularization in vitro in a dynamic direct perfusion bioreactor.
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Figure 6.1. Schematic representation of direct perfusion bioreactor. In direct perfusion
bioreactors the cell/scaffold constructs are placed in a press-fitted fashion in the culture chamber
and the medium is perfused throughout the constructs.

To design the bioreactor system, microtubular shells with 8 mm outer diameter and 3
mm wall thickness will be used to direct the flow of osteogenic medium in the hioreactor
of a perfusion cell culture. The interconnected microcanals of the shell will be injected
with a mixture of BMP2 (200 ng/mL) and 5xlob hMSCs in collagen type I. The scaffolds
will be press-fitted into a silicone tube to yield the bioreactor section of the perfusion
system (Figure 6.2 b). The medium will be oxygenated in the reservoir which has one
inlet and 16 outlets to allow simultaneous perfusion of 16 shells (Figure 6.2 a).
Factors that affect the transport of nutrients and oxygen in the central part of the
engineered shell-core graft are the spacing between the Volkmann canals in the rigid
shell and the spacing between the microchannels in the soft core (Figure 1.2).
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Figure 6.2. 16 perfusion bioreactors in parallel (arrow shows one of the reactors). (b) The
perfusion cell culture system.

The average wall thickness of osteons in the native compact bone is 150 µm

180

.

Therefore for 5-µm microsheet thickness, microtubes will consist of 30 lamellar layers.
The spacing between the Volkmann canals in the natural bone varies between 500-1000
µm 181. Therefore, microdrilling will be used to vary the spacing between the Volkmannlike canals in the engineered graft from 500 to 750 and 1000 µm. The spacing between
the needles in the soft GeIMA gel will also be varied from 500 to 750 and 1000 µm. The
rigid shell will be synthesized as described before

181

. An array of circular microholes

with intervals of 500, 750, or 1000 µm will be drilled by laser microdrilling on the
outside surface of the shell traversing the shell thickness. Next, the shell will be sterilized
and all subsequent steps will be done under sterile condition. Then, needles with
separation distance of 500-1000 µm will be placed inside the shell through an end-cap.
The sterile GeIMA precursor solution, NG-VEGF, and human MSCs+EPCs (50:50, 2xl06
cells/ml of GeLMA) will be injected between the needles and cross-linked with UV as we
described previously 182 and needles are removed. Finally, the interconnected microcanals
87

of the shell wall will be filled with NG-BMP2 and human MSCs (2x106 cells/ml
collagen) in collagen type I solution. The cellular constructs with timed-release of growth
factors will be press-fitted into a silicone tube as the bioreactor section of the perfusion
system (Figure 6.2 b) and culture medium will pumped through the bioreactors at the rate
of 0.5 mL/min for 21 days as described. At each time point (1, 3,7. 10, 14. 21), the
middle section of the graft will he characterized with respect to cellularity, extent of
mineralization, and extent of vascularization as we previously described

134, 182, 183

.

Microvessels will be visualized with Image ProPlus software to determine uniformity and
total capillary density as described 35.

88

REFERENCES
1.

Salgado, A.n.J., O.P. Coutinho, and R.L. Reis, Bone tissue engineering: state of
the art and future trends. Macromolecular bioscience, 2004. 4(8): p. 743-765.

2.

Sikavitsas, V.I., J.S. Temenoff, and A.G. Mikos, Biomaterials and bone
mechanotransduction. Biomaterials, 2001. 22(19): p. 2581-2593.

3.

Turner, C.H., T. Wang, and D.B. Burr, Shear strength and fatigue properties of
human cortical bone determined from pure shear tests. Calcified tissue
international, 2001. 69(6): p. 373-378.

4.

Rodan, G.A., Introduction to bone biology. Bone, 1992. 13: p. S3-S6.

5.

Siemionow, M., et al., Composite vascularized skin/bone graft model: a viable
source for vascularized bone marrow transplantation. Microsurgery, 2004. 24(3):
p. 200-206.

6.

FrÃ¶hlich, M., et al., Tissue engineered bone grafts: biological requirements,
tissue culture and clinical relevance. Current stem cell research & therapy, 2008.
3(4): p. 254.

7.

Burg, K.J.L., S. Porter, and J.F. Kellam, Biomaterial developments for bone tissue
engineering. Biomaterials, 2000. 21(23): p. 2347-2359.

8.

Zhang, P., K. Hamamura, and H. Yokota, A brief review of bone adaptation to
unloading. Genomics, proteomics & bioinformatics, 2008. 6(1): p. 4-7.

9.

Simon, J.A., J.L. Ricci, and P.E. Di Cesare, Bioresorbable fracture fixation in
orthopedics: a comprehensive review. Part I. Basic science and preclinical
studies. American journal of orthopedics (Belle Mead, NJ), 1997. 26(10): p. 665671.

10.

Porter, J.R., T.T. Ruckh, and K.C. Popat, Bone Tissue Engineering: A Review in
Bone Biomimetics and Drug Delivery Strategies. Biotechnology Progress, 2009.
25(6): p. 1539-1560.

11.

Sargeant, T.D., et al., Hybrid bone implants: self-assembly of peptide amphiphile
nanofibers within porous titanium. Biomaterials, 2008. 29(2): p. 161-171.

12.

Nakahara, H., et al., Bone repair using a hybrid scaffold of self-assembling
peptide PuraMatrix and polyetheretherketone cage in rats. Cell transplantation.
19(6-7): p. 791-797.

89

13.

Peppas, N.A., et al., Hydrogels in biology and medicine: from molecular
principles to bionanotechnology. Advanced Materials, 2006. 18(11): p. 13451360.

14.

Drury, J.L. and D.J. Mooney, Hydrogels for tissue engineering: scaffold design
variables and applications. Biomaterials, 2003. 24(24): p. 4337-4351.

15.

Burdick, J.A. and K.S. Anseth, Photoencapsulation of osteoblasts in injectable
RGD-modified PEG hydrogels for bone tissue engineering. Biomaterials, 2002.
23(22): p. 4315-4323.

16.

Igwe, J.C., P.E. Mikael, and S.P. Nukavarapu, Design, fabrication and in vitro
evaluation of a novel polymerâ€ hydrogel hybrid scaffold for bone tissue
engineering. Journal of tissue engineering and regenerative medicine. 8(2): p.
131-142.

17.

Nguyen, J., et al., Load regulates bone formation and Sclerostin expression
through a TGFbeta-dependent mechanism. PloS one. 8(1): p. e53813.

18.

Jonitz, A., et al., Oxygen consumption, acidification and migration capacity of
human primary osteoblasts within a three-dimensional tantalum scaffold. Journal
of Materials Science: Materials in Medicine. 22(9): p. 2089-2095.

19.

Levesque, J.P., F.M. Helwani, and I.G. Winkler, The endosteal
â€˜osteoblasticâ€™niche and its role in hematopoietic stem cell homing and
mobilization. Leukemia. 24(12): p. 1979-1992.

20.

Carano, R.A.D. and E.H. Filvaroff, Angiogenesis and bone repair. Drug
discovery today, 2003. 8(21): p. 980-989.

21.

Kopp, H.G., et al., Functional heterogeneity of the bone marrow vascular niche.
Annals of the New York Academy of Sciences, 2009. 1176(1): p. 47-54.

22.

Rabie, A.B.M. and U. HÃ¤gg, Factors regulating mandibular condylar growth.
American Journal of Orthodontics and Dentofacial Orthopedics, 2002. 122(4): p.
401-409.

23.

Amini, A.R., C.T. Laurencin, and S.P. Nukavarapu, Bone tissue engineering:
recent advances and challenges. Critical Reviewsâ„¢ in Biomedical Engineering.
40(5).

24.

Huang, Z., et al., The sequential expression profiles of growth factors from
osteroprogenitors to osteoblasts in vitro. Tissue engineering, 2007. 13(9): p.
2311-2320.

25.

Devescovi, V., et al., Growth factors in bone repair. La Chirurgia degli organi di
movimento, 2008. 92(3): p. 161-168.

26.

Malizos, K.N. and L.K. Papatheodorou, The healing potential of the periosteum:
molecular aspects. Injury, 2005. 36(3): p. S13-S19.

90

27.

Collinâ€ Osdoby, P., et al., Basic fibroblast growth factor stimulates osteoclast
recruitment, development, and bone pit resorption in association with
angiogenesis in vivo on the chick chorioallantoic membrane and activates
isolated avian osteoclast resorption in vitro. Journal of Bone and Mineral
Research, 2002. 17(10): p. 1859-1871.

28.

Kanczler, J.M. and R.O. Oreffo, Osteogenesis and angiogenesis: the potential for
engineering bone. Eur Cell Mater, 2008. 15(2): p. 100-114.

29.

Matassi, F., et al., New biomaterials for bone regeneration. Clinical cases in
mineral and bone metabolism. 8(1): p. 21-24.

30.

Takahashi, Y., M. Yamamoto, and Y. Tabata, Enhanced osteoinduction by
controlled release of bone morphogenetic protein-2 from biodegradable sponge
composed of gelatin and Î²-tricalcium phosphate. Biomaterials, 2005. 26(23): p.
4856-4865.

31.

Kaneko, H., et al., Direct stimulation of osteoclastic bone resorption by bone
morphogenetic protein (BMP)-2 and expression of BMP receptors in mature
osteoclasts. Bone, 2000. 27(4): p. 479-486.

32.

Raida, M., et al., Role of bone morphogenetic protein 2 in the crosstalk between
endothelial progenitor cells and mesenchymal stem cells. International journal of
molecular medicine, 2006. 18(4): p. 735-739.

33.

Park, J.C., et al., Doseâ€ and timeâ€ dependent effects of recombinant human
bone morphogenetic proteinâ€ 2 on the osteogenic and adipogenic potentials of
alveolar boneâ€ derived stromal cells. Journal of periodontal research. 47(5): p.
645-654.

34.

Jeon, O., et al., Long-term delivery enhances in vivo osteogenic efficacy of bone
morphogenetic protein-2 compared to short-term delivery. Biochemical and
biophysical research communications, 2008. 369(2): p. 774-780.

35.

Chen, Y.C., et al., Functional human vascular network generated in
photocrosslinkable gelatin methacrylate hydrogels. Advanced functional
materials. 22(10): p. 2027-2039.

36.

Logeart-Avramoglou, D., et al., Engineering bone: challenges and obstacles.
Journal of Cellular and Molecular Medicine, 2005. 9(1): p. 72-84.

37.

Yasuda, H., et al., Repair of critical long bone defects using frozen bone
allografts coated with an rhBMP-2-retaining paste. Journal of Orthopaedic
Science, 2012. 17(3): p. 299-307.

38.

Wheeler, D.L. and W.F. Enneking, Allograft bone decreases in strength in vivo
over time. Clinical Orthopaedics and Related Research, 2005(435): p. 36-42.

39.

Gruskin, E., et al., Demineralized bone matrix in bone repair: History and use.
Advanced Drug Delivery Reviews, 2012. 64(12): p. 1063-1077.

40.

Hench, L.L. and J.M. Polak, Third-generation biomedical materials. Science,
2002. 295(5557): p. 1014-+.
91

41.

Causa, F., et al., Poly-epsilon-caprolactone/hydroxyapatite composites for bone
regeneration: in vitro characterization and human osteoblast response. Journal of
Biomedical Materials Research Part A, 2006. 76A(1): p. 151-162.

42.

Karaman, O., Effect of Surface Modification of Nanofibers with Glutamic Acid
Peptide on Calcium Phosphate Nucleation and Osteogenic Differentiation of
Marrow Stromal Cells. Journal of Tissue Engineering and Regenerative
Medicine, 2013.

43.

Moore, W.R., S.E. Graves, and G.I. Bain, Synthetic bone graft substitutes.
Australian and New Zealand Journal of Surgery, 2001. 71(6): p. 354-361.

44.

Lindner, M., et al., Calcium phosphate scaffolds mimicking the gradient
architecture of native long bones. Journal of Biomedical Materials Research Part
A, 2014. 102(10): p. 3677-3684.

45.

Shin, Y.M., et al., Promotion of human mesenchymal stem cell differentiation on
bioresorbable polycaprolactone/biphasic calcium phosphate composite scaffolds
for bone tissue engineering. Biotechnology and Bioprocess Engineering, 2014.
19(2): p. 341-349.

46.

Kim, J.W., et al., Volumetric bone regenerative efficacy of biphasic calcium
phosphate-collagen composite block loaded with rhBMP-2 in vertical bone
augmentation model of a rabbit calvarium (vol 100, pg 3304, 2012). Journal of
Biomedical Materials Research Part A, 2013. 101(4): p. 1223-1223.

47.

Ma, Z., et al., Amorphous calcium phosphate/poly(D,L-lactic acid) composite
nanofibers: Electrospinning preparation and biomineralization. Journal of
Colloid and Interface Science, 2011. 359(2): p. 371-379.

48.

van de Watering, F.C.J., et al., Calcium phosphate/poly(D,L-lactic-co-glycolic
acid) composite bone substitute materials: evaluation of temporal degradation
and bone ingrowth in a rat critical-sized cranial defect. Clinical Oral Implants
Research, 2012. 23(2): p. 151-159.

49.

Hamada, Y., et al., The preparation of PLLA/calcium phosphate hybrid composite
and its evaluation of biocompatibility. Dental Materials Journal, 2012. 31(6): p.
1087-1096.

50.

Wang, Q., et al., In situ remineralizaiton of partially demineralized human
dentine mediated by a biomimetic non-collagen peptide. Soft Matter, 2011. 7(20):
p. 9673-9680.

51.

Sarvestani, A.S., X. He, and E. Jabbari, Osteonectin-derived peptide increases the
modulus of a bone-mimetic nanocomposite. European Biophysics Journal with
Biophysics Letters, 2008. 37(2): p. 229-234.

52.

Li, B. and R.M. Aspden, Composition and mechanical properties of cancellous
bone from the femoral head of patients with osteoporosis or osteoarthritis.
Journal of Bone and Mineral Research, 1997. 12(4): p. 641-651.

92

53.

Xie, B.Q. and G.H. Nancollas, How to control the size and morphology of apatite
nanocrystals in bone. Proceedings of the National Academy of Sciences of the
United States of America, 2010. 107(52): p. 22369-22370.

54.

Hu, Y.Y., A. Rawal, and K. Schmidt-Rohr, Strongly bound citrate stabilizes the
apatite nanocrystals in bone. Proceedings of the National Academy of Sciences of
the United States of America, 2010. 107(52): p. 22425-22429.

55.

Brecevic, L. and H. Furedimilhofer, Precipitation of Calcium Phosphates from
Electrolyte-Solutions .5. Influence of Citrate Ions. Calcified Tissue International,
1979. 28(2): p. 131-136.

56.

Hempel, U., et al., Proliferation and differentiation of osteoblasts on biocement D
modified with collagen type I and citric acid. Journal of Biomedical Materials
Research Part B-Applied Biomaterials, 2004. 71B(1): p. 130-143.

57.

Chung, E.J., M.J. Sugimoto, and G.A. Ameer, The role of hydroxyapatite in citric
acid-based nanocomposites: Surface characteristics, degradation, and
osteogenicity in vitro. Acta Biomaterialia, 2011. 7(11): p. 4057-4063.

58.

Sarda, S., et al., Kinetic study of citric acid influence on calcium phosphate bone
cements as water-reducing agent. Journal of Biomedical Materials Research,
2002. 61(4): p. 653-659.

59.

Rhee, S.H. and J. Tanaka, Effect of citric acid on the nucleation of hydroxyapatite
in a simulated body fluid. Biomaterials, 1999. 20(22): p. 2155-2160.

60.

Etienne, A., et al., What controls fleshy fruit acidity? A review of malate and
citrate accumulation in fruit cells. Journal of Experimental Botany, 2013. 64(6):
p. 1451-1469.

61.

Umadevi, M., M.R. Bindhu, and V. Sathe, A Novel Synthesis of Malic Acid
Capped Silver Nanoparticles using Solanum lycopersicums Fruit Extract. Journal
of Materials Science & Technology, 2013. 29(4): p. 317-322.

62.

Duthie, G.G. and A.D. Wood, Natural salicylates: foods, functions and disease
prevention. Food & Function, 2011. 2(9): p. 515-520.

63.

DeBolt, S., D.R. Cook, and C.M. Ford, L-Tartaric acid synthesis from vitamin C
in higher plants. Proceedings of the National Academy of Sciences of the United
States of America, 2006. 103(14): p. 5608-5613.

64.

Hoffman, J.R., et al., Thermogenic Effect from Nutritionally Enriched Coffee
Consumption. Journal of the International Society of Sports Nutrition, 2006. 3.

65.

Ma, J., X. He, and E. Jabbari, Osteogenic Differentiation of Marrow Stromal
Cells on Random and Aligned Electrospun Poly(L-lactide) Nanofibers. Annals of
Biomedical Engineering, 2011. 39(1).

66.

Xu, C.Y., et al., Aligned biodegradable nanofibrous structure: a potential scaffold
for blood vessel engineering. Biomaterials, 2004. 25(5): p. 877-886.

93

67.

Yang, F., et al., Electrospinning of nano/micro scale poly(l-lactic acid) aligned
fibers and their potential in neural tissue engineering. Biomaterials, 2005. 26(15):
p. 2603-2610.

68.

da Cunha, C.B., et al., Influence of the stiffness of three-dimensional
alginate/collagen-I interpenetrating networks on fibroblast biology. Biomaterials,
2014. 35(32): p. 8927-8936.

69.

Patterson, A.L., The Scherrer formula for x-ray particle size determination.
Physical Review, 1939. 56(10): p. 978-982.

70.

Sanosh, K.P., et al., Preparation and characterization of nano-hydroxyapatite
powder using sol-gel technique. Bulletin of Materials Science, 2009. 32(5): p.
465-470.

71.

Stipniece, L., et al., The Study of Magnesium Substitution Effect on
Physicochemical Properties of Hydroxyapatite. Material Science and Applied
Chemistry. 28(28): p. 51-57.

72.

Martins, M.A., et al., Hydroxyapatite micro- and nanoparticles: Nucleation and
growth mechanisms in the presence of citrate species. Journal of Colloid and
Interface Science, 2008. 318(2): p. 210-216.

73.

Landi, E., et al., Densification behaviour and mechanisms of synthetic
hydroxyapatites. Journal of the European Ceramic Society, 2000. 20(14-15): p.
2377-2387.

74.

Danial Barati , S.M., Ozan Karaman , Esmaiel Jabbari, Time Dependence of
Material Properties of Polyethylene Glycol Hydrogels Chain Extended with Short
Hydroxy Acid Segments. Polymer, 2014. S0032-3861(14)00433-9.

75.

Moeinzadeh, S., et al., Gelation Characteristics and Osteogenic Differentiation of
Stromal Cells in Inert Hydrolytically Degradable Micellar Polyethylene Glycol
Hydrogels. Biomacromolecules, 2012. 13(7): p. 2073-2086.

76.

He, C.L., X.B. Jin, and P.X. Ma, Calcium phosphate deposition rate, structure
and osteoconductivity on electrospun poly(L-lactic acid) matrix using
electrodeposition or simulated body fluid incubation. Acta Biomaterialia, 2014.
10(1): p. 419-427.

77.

Boanini, E., M. Gazzano, and A. Bigi, Ionic substitutions in calcium phosphates
synthesized at low temperature. Acta Biomaterialia, 2010. 6(6): p. 1882-1894.

78.

Meng, Z.X., et al., Fabrication of mineralized electrospun PLGA and
PLGA/gelatin nanofibers and their potential in bone tissue engineering. Materials
Science & Engineering C-Materials for Biological Applications, 2013. 33(2): p.
699-706.

79.

Wang, X.Y., et al., Comparative Study on Inorganic Composition and
Crystallographic Properties of Cortical and Cancellous Bone. Biomedical and
Environmental Sciences, 2010. 23(6): p. 473-480.

94

80.

Schecroun, N. and C. Delloye, Bone-like nodules formed by human bone marrow
stromal cells: comparative study and characterizationâ˜†. Bone, 2003. 32(3): p.
252-260.

81.

Tsigkou, O., et al., Differentiation of fetal osteoblasts and formation of
mineralized bone nodules by 45S5 Bioglass (R) conditioned medium in the
absence of osteogenic supplements. Biomaterials, 2009. 30(21): p. 3542-3550.

82.

Barralet, J.E., et al., Modification of calcium phosphate cement with alphahydroxy acids and their salts. Chemistry of Materials, 2005. 17(6): p. 1313-1319.

83.

Wang, X., A theory for the mechanism of action of the Î±-hydroxy acids applied
to the skin. Medical hypotheses, 1999. 53(5): p. 380-382.

84.

LeGeros, R.Z., Formation and transformation of calcium phosphates: relevance
to vascular calcification. Zeitschrift fÃ¼r Kardiologie, 2001. 90(3): p. 116-124.

85.

Chou, L., B. Marek, and W.R. Wagner, Effects of hydroxylapatite coating
crystallinity on biosolubility, cell attachment efficiency and proliferation in vitro.
Biomaterials, 1999. 20(10): p. 977-985.

86.

Zhang, W., et al., Effect of calcium citrate on bone integration in a rabbit femur
defect model. Asian Pacific Journal of Tropical Medicine, 2012. 5(4): p. 310-314.

87.

Raucci, M.G., et al., Effect of citric acid crosslinking celluloseâ€ based
hydrogels on osteogenic differentiation. Journal of Biomedical Materials
Research Part A.

88.

Langenbach, F. and J. Handschel, Effects of dexamethasone, ascorbic acid and
beta-glycerophosphate on the osteogenic differentiation of stem cells in vitro.
Stem Cell Research & Therapy, 2013. 4.

89.

Damien, C.J. and J.R. Parsons, Bone graft and bone graft substitutes: A review of
current technology and applications. Journal of Applied Biomaterials, 1991. 2(3):
p. 187-208.

90.

Scheller, E.L., P.H. Krebsbach, and D.H. Kohn, Tissue engineering: state of the
art in oral rehabilitation. Journal of Oral Rehabilitation, 2009. 36(5): p. 368-389.

91.

Kretlow, J.D., et al., Injectable Biomaterials for Regenerating Complex
Craniofacial Tissues. Advanced Materials, 2009. 21(32-33): p. 3368-3393.

92.

Frohlich, M., et al., Tissue Engineered Bone Grafts: Biological Requirements,
Tissue Culture and Clinical Relevance. Current Stem Cell Research & Therapy,
2008. 3(4): p. 254-264.

93.

van Oers, R.F.M., et al., Relating osteon diameter to strain. Bone, 2008. 43(3): p.
476-482.

94.

Even-Ram, S. and K.M. Yamada, Cell migration in 3D matrix. Current Opinion
in Cell Biology, 2005. 17(5): p. 524-532.

95.

Bartold, P.M., et al., Tissue engineering: a new paradigm for periodontal
regeneration based on molecular and cell biology. Periodontology 2000, 2000.
24: p. 253-269.
95

96.

Chen, J.-P. and Y.-S. Chang, Preparation and characterization of composite
nanofibers of polycaprolactone and nanohydroxyapatite for osteogenic
differentiation of mesenchymal stem cells. Colloids and Surfaces B: Biointerfaces,
2011. 86(1): p. 169-175.

97.

Bolander, M.E., et al., Osteonectin Cdna Sequence Reveals Potential Binding
Regions for Calcium and Hydroxyapatite and Shows Homologies with Both a
Basement-Membrane Protein (Sparc) and a Serine Proteinase-Inhibitor
(Ovomucoid). Proceedings of the National Academy of Sciences of the United
States of America, 1988. 85(9): p. 2919-2923.

98.

Oldberg, A., A. Franzen, and D. Heinegard, The Primary Structure of a CellBinding Bone Sialoprotein. Journal of Biological Chemistry, 1988. 263(36): p.
19430-19432.

99.

Itoh, D., et al., Enhancement of osteogenesis on hydroxyapatite surface coated
with synthetic peptide (EEEEEEEPRGDT) in vitro. Journal of Biomedical
Materials Research, 2002. 62(2): p. 292-298.

100.

Sarvestani, A., X. He, and E. Jabbari, Osteonectin-derived peptide increases the
modulus of a bone-mimetic nanocomposite. European Biophysics Journal, 2008.
37(2): p. 229-234.

101.

Schulz, A., Bone-Structure and Remodeling Dynamics in Osteopathies. Zeitschrift
Fur Rheumatologie, 1988. 47(4): p. 309-310.

102.

Athanasiou, K.A., et al., Fundamentals of biomechanics in tissue engineering of
bone. Tissue engineering, 2000. 6(4): p. 361-381.

103.

Ascenzi, A. and E. Bonucci, The compressive properties of single osteons. The
Anatomical Record, 1968. 161(3): p. 377-391.

104.

Miyazaki, T., et al., Mechanism of bonelike apatite formation on bioactive
tantalum metal in a simulated body fluid. Biomaterials, 2002. 23(3): p. 827-832.

105.

Liu, W., et al., Enhancing the Stiffness of Electrospun Nanofiber Scaffolds with a
Controlled Surface Coating and Mineralization. Langmuir, 2011. 27(15): p.
9088-9093.

106.

Thomas, V., et al., Electrospun bioactive nanocomposite scaffolds of
polycaprolactone and nanohydroxyapatite for bone tissue engineering. Journal of
Nanoscience and Nanotechnology, 2006. 6(2): p. 487-493.

107.

Li, X., et al., Nanofiber Scaffolds with Gradations in Mineral Content for
Mimicking the Tendon-to-Bone Insertion Site. Nano Letters, 2009. 9(7): p. 27632768.

108.

Holzwarth, J.M. and P.X. Ma, 3D nanofibrous scaffolds for tissue engineering.
Journal of Materials Chemistry, 2011. 21(28): p. 10243-10251.

109.

Gaggl, A., H. Rainer, and F.M. Chiari, Horizontal distraction of the anterior
maxilla in combination with bilateral sinuslift operationâ€”preliminary report.
International journal of oral and maxillofacial surgery, 2005. 34(1): p. 37-44.
96

110.

Fischgrund, J., D. Paley, and C. Suter, Variables affecting time to bone healing
during limb lengthening. Clinical orthopaedics and related research, 1994. 301: p.
31-37.

111.

Malo, M.K.H., et al., Longitudinal elastic properties and porosity of cortical bone
tissue vary with age in human proximal femur. Bone. 53(2): p. 451-458.

112.

Bae, S.E., et al., Controlled release of bone morphogenetic protein (BMP)-2 from
nanocomplex incorporated on hydroxyapatite-formed titanium surface. Journal of
controlled release. 160(3): p. 676-684.

113.

Gerstenfeld, L.C., et al., Fracture healing as a postâ€ natal developmental
process: Molecular, spatial, and temporal aspects of its regulation. Journal of
cellular biochemistry, 2003. 88(5): p. 873-884.

114.

Bostrom, M.P.G., Expression of bone morphogenetic proteins in fracture healing.
Clinical orthopaedics and related research, 1998. 355: p. S116-S123.

115.

Street, J., et al., Vascular endothelial growth factor stimulates bone repair by
promoting angiogenesis and bone turnover. Proceedings of the National Academy
of Sciences, 2002. 99(15): p. 9656-9661.

116.

Jones, A.L., et al., Recombinant human BMP-2 and allograft compared with
autogenous bone graft for reconstruction of diaphyseal tibial fractures with
cortical defectsA randomized, controlled trial. The Journal of Bone & Joint
Surgery, 2006. 88(7): p. 1431-1441.

117.

Eppler, S.M., et al., A target-mediated model to describe the pharmacokinetics
and hemodynamic effects of recombinant human vascular endothelial growth
factor in humans. CLINICAL PHARMACOLOGY AND THERAPEUTICS-ST
LOUIS-, 2002. 72(1): p. 20-32.

118.

Mercado, A.E., et al., Release characteristics and osteogenic activity of
recombinant human bone morphogenetic protein-2 grafted to novel selfassembled poly(lactide-co-glycolide fumarate) nanoparticles. Journal of
controlled release, 2009. 140(2): p. 148-156.

119.

Mercado, A.E., et al., The release characteristics of a model protein from selfassembled succinimide-terminated poly (lactide-co-glycolide ethylene oxide
fumarate) nanoparticles. Nanotechnology, 2008. 19(32): p. 325609.

120.

Li, Y.-P., et al., PEGylated PLGA nanoparticles as protein carriers: synthesis,
preparation and biodistribution in rats. Journal of controlled release, 2001. 71(2):
p. 203-211.

121.

Chung, Y.-I., et al., Enhanced bone regeneration with BMP-2 loaded functional
nanoparticle-hydrogel complex. Journal of controlled release, 2007. 121(1): p. 9199.

122.

Zhu, G., S.R. Mallery, and S.P. Schwendeman, Stabilization of proteins
encapsulated in injectable poly (lactide-co-glycolide). Nature biotechnology,
2000. 18(1): p. 52-57.
97

123.

Crotts, G., H. Sah, and T.G. Park, Adsorption determines in-vitro protein release
rate from biodegradable microspheres: quantitative analysis of surface area
during degradation. Journal of controlled release, 1997. 47(1): p. 101-111.

124.

Gref, R., et al., The controlled intravenous delivery of drugs using PEG-coated
sterically stabilized nanospheres. Advanced drug delivery reviews, 1995. 16(2):
p. 215-233.

125.

Zhang, S., et al., Polyethylenimine PEG coated albumin nanoparticles for BMP-2
delivery. Biomaterials, 2009. 31(5): p. 952-963.

126.

Simon-Yarza, T., et al., PEGylated-PLGA microparticles containing VEGF for
long term drug delivery. International journal of pharmaceutics, 2013. 440(1): p.
13-18.

127.

Moeinzadeh, S., et al., Nanostructure Formation and Transition from Surface to
Bulk Degradation in Polyethylene Glycol Gels Chain-Extended with Short
Hydroxy Acid Segments. Biomacromolecules, 2013. 14(8): p. 2917-2928.

128.

Mercado, A.E. and E. Jabbari, Effect of encapsulation or grafting on release
kinetics of recombinant human bone morphogenetic protein-2 from selfassembled poly (lactide-co-glycolide ethylene oxide fumarate) nanoparticles.
Microscopy Research and Technique, 2010. 73(9): p. 824-833.

129.

He, X.Z. and E. Jabbari, Material properties and cytocompatibility of injectable
MMP degradable poly(lactide ethylene oxide fumarate) hydrogel as a carrier for
marrow stromal cells. Biomacromolecules, 2007. 8(3): p. 780-792.

130.

He, X., X. Yang, and E. Jabbari, Combined effect of osteopontin and BMP-2
derived peptides grafted to an adhesive hydrogel on osteogenic and vasculogenic
differentiation of marrow stromal cells. Langmuir, 2012. 28(12): p. 5387-97.

131.

Mirshahghassemi, S., B. Cai, and J.R. Lead, Evaluation of polymer-coated
magnetic nanoparticles for oil separation under environmentally relevant
conditions: effect of ionic strength and natural organic macromolecules.
Environmental Science: Nano.

132.

Afshinnia, K., et al., The concentration-dependent aggregation of Ag NPs induced
by cystine. Science of The Total Environment. 557: p. 395-403.

133.

Mirshahghassemi, S. and J.R. Lead, Oil Recovery from Water under
Environmentally Relevant Conditions Using Magnetic Nanoparticles.
Environmental Science & Technology, 2015. 49(19): p. 11729-11736.

134.

Barati, D., et al., Time dependence of material properties of polyethylene glycol
hydrogels chain extended with short hydroxy acid segments. Polymer, 2014.
55(16): p. 3894-3904.

135.

Park, J.C., et al., Dose- and time-dependent effects of recombinant human bone
morphogenetic protein-2 on the osteogenic and adipogenic potentials of alveolar
bone-derived stromal cells. J Periodontal Res, 2012. 47(5): p. 645-54.

98

136.

Jeon, O., et al., Long-term delivery enhances in vivo osteogenic efficacy of bone
morphogenetic protein-2 compared to short-term delivery. Biochemical and
biophysical research communications, 2008. 369(2): p. 774-780.

137.

Chen, Y.C., et al., Functional Human Vascular Network Generated in
Photocrosslinkable Gelatin Methacrylate Hydrogels. Advanced Functional
Materials, 2012. 22(10): p. 2027-2039.

138.

Forster, S., et al., Micellization of strongly segregated block copolymers. The
Journal of chemical physics, 1996. 104(24): p. 9956-9970.

139.

Jokerst, J.V., et al., Nanoparticle PEGylation for imaging and therapy.
Nanomedicine, 2011. 6(4): p. 715-728.

140.

Riley, T., et al., Colloidal stability and drug incorporation aspects of micellar-like
PLA-PEG nanoparticles. Colloids and surfaces B: Biointerfaces, 1999. 16(1): p.
147-159.

141.

Beletsi, A., Z. Panagi, and K. Avgoustakis, Biodistribution properties of
nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers.
International journal of pharmaceutics, 2005. 298(1): p. 233-241.

142.

Zweers, M.L.T., et al., In vitro degradation of nanoparticles prepared from
polymers based on DL-lactide, glycolide and poly (ethylene oxide). Journal of
controlled release, 2004. 100(3): p. 347-356.

143.

Avgoustakis, K., et al., PLGA-mPEG nanoparticles of cisplatin: in vitro
nanoparticle degradation, in vitro drug release and in vivo drug residence in
blood properties. Journal of controlled release, 2002. 79(1): p. 123-135.

144.

Youxin, L. and T. Kissel, Synthesis and properties of biodegradable ABA triblock
copolymers consisting of poly (L-lactic acid) or poly (L-lactic-co-glycolic acid) Ablocks attached to central poly (oxyethylene) B-blocks. Journal of controlled
release, 1993. 27(3): p. 247-257.

145.

Molina, C.S., D.J. Stinner, and W.T. Obremskey, Treatment of traumatic
segmental long-bone defects: A critical analysis review. JBJS Reviews, 2014.
2(4): p. e1.

146.

Yasuda, H., et al., Repair of critical long bone defects using frozen bone
allografts coated with an rhBMP-2-retaining paste. J Orthop Sci, 2012. 17(3): p.
299-307.

147.

Lissenberg-Thunnissen, S.N., et al., Use and efficacy of bone morphogenetic
proteins in fracture healing. International Orthopaedics, 2011. 35(9): p. 12711280.

148.

Carragee, E.J., E.L. Hurwitz, and B.K. Weiner, A critical review of recombinant
human bone morphogenetic protein-2 trials in spinal surgery: emerging safety
concerns and lessons learned. Spine Journal, 2011. 11(6): p. 471-491.

149.

Yang, Y.Q., et al., The role of vascular endothelial growth factor in ossification.
International Journal of Oral Science, 2012. 4(2): p. 64-68.
99

150.

Poldervaart, M.T., et al., Prolonged presence of VEGF promotes vascularization
in 3D bioprinted scaffolds with defined architecture. Journal of controlled release,
2014. 184: p. 58-66.

151.

Kleinheinz, J., et al., Release kinetics of VEGF165 from a collagen matrix and
structural matrix changes in a circulation model. Head & Face Medicine, 2010.
6(1): p. 17.

152.

Bae, S.E., et al., Controlled release of bone morphogenetic protein (BMP)-2 from
nanocomplex incorporated on hydroxyapatite-formed titanium surface. Journal of
controlled release, 2012. 160(3): p. 676-684.

153.

Levesque, J.P., F.M. Helwani, and I.G. Winkler, The endosteal 'osteoblastic'
niche and its role in hematopoietic stem cell homing and mobilization. Leukemia,
2010. 24(12): p. 1979-1992.

154.

Dai, J. and A.B.M. Rabie, VEGF: an essential mediator of both angiogenesis and
endochondral ossification. Journal of Dental Research, 2007. 86(10): p. 937-950.

155.

Rabie, A.B.M. and U. Hagg, Factors regulating mandibular condylar growth.
American Journal of Orthodontics and Dentofacial Orthopedics, 2002. 122(4): p.
401-409.

156.

Kopp, H.G., et al., Functional Heterogeneity of the Bone Marrow Vascular Niche.
Hematopoietic Stem Cells Vii, 2009. 1176: p. 47-54.

157.

Lin, Z.W., et al., Effects of BMP2 and VEGF165 on the osteogenic differentiation
of rat bone marrow-derived mesenchymal stem cells. Experimental and
Therapeutic Medicine, 2014. 7(3): p. 625-629.

158.

He, X.N., et al., BMP2 Genetically Engineered MSCs and EPCs Promote
Vascularized Bone Regeneration in Rat Critical-Sized Calvarial Bone Defects.
Plos One, 2013. 8(4).

159.

Lin, R.Z., et al., Human endothelial colony-forming cells serve as trophic
mediators for mesenchymal stem cell engraftment via paracrine signaling.
Proceedings of the National Academy of Sciences of the United States of
America, 2014. 111(28): p. 10137-10142.

160.

Geuze, R.E., et al., A Differential Effect of Bone Morphogenetic Protein-2 and
Vascular Endothelial Growth Factor Release Timing on Osteogenesis at Ectopic
and Orthotopic Sites in a Large-Animal Model. Tissue Engineering Part A, 2012.
18(19-20): p. 2052-2062.

161.

Song, X.B., et al., BMP2 and VEGF promote angiogenesis but retard terminal
differentiation of osteoblasts in bone regeneration by up-regulating Id1. Acta
Biochimica Et Biophysica Sinica, 2011. 43(10): p. 796-804.

162.

Patel, Z.S., et al., Dual delivery of an angiogenic and an osteogenic growth factor
for bone regeneration in a critical size defect model. Bone, 2008. 43(5): p. 931940.

100

163.

Kempen, D.H.R., et al., Effect of local sequential VEGF and BMP-2 delivery on
ectopic and orthotopic bone regeneration. Biomaterials, 2009. 30(14): p. 28162825.

164.

Matsubara, H., et al., Vascular tissues are a primary source of BMP2 expression
during bone formation induced by distraction osteogenesis. Bone, 2012. 51(1): p.
168-180.

165.

Moeinzadeh, S., et al., Gelation characteristics and osteogenic differentiation of
stromal cells in inert hydrolytically degradable micellar polyethylene glycol
hydrogels. Biomacromolecules, 2012. 13(7): p. 2073-2086.

166.

Kim, J.M., et al., DJ-1 promotes angiogenesis and osteogenesis by activating
FGF receptor-1 signaling. Nature Communications, 2012. 3.

167.

Qu, D., et al., Angiogenesis and osteogenesis enhanced by bFGF ex vivo gene
therapy for bone tissue engineering in reconstruction of calvarial defects. Journal
of Biomedical Materials Research Part A, 2011. 96A(3): p. 543-551.

168.

des Rieux, A., et al., 3D systems delivering VEGF to promote angiogenesis for
tissue engineering. Journal of controlled release, 2011. 150(3): p. 272-278.

169.

Formiga, F.R., et al., Sustained release of VEGF through PLGA microparticles
improves vasculogenesis and tissue remodeling in an acute myocardial ischemiareperfusion model. Journal of controlled release, 2010. 147(1): p. 30-37.

170.

Wang, Z., et al., BMP-2 encapsulated polysaccharide nanoparticle modified
biphasic calcium phosphate scaffolds for bone tissue regeneration. Journal of
Biomedical Materials Research Part A, 2015.

171.

Goldstein, A.S., et al., Effect of convection on osteoblastic cell growth and
function in biodegradable polymer foam scaffolds. Biomaterials, 2001. 22(11): p.
1279-1288.

172.

Yeatts, A.B. and J.P. Fisher, Bone tissue engineering bioreactors: dynamic
culture and the influence of shear stress. Bone. 48(2): p. 171-181.

173.

Klein-Nulend, J., et al., Mechanosensation and transduction in osteocytes. Bone.
54(2): p. 182-190.

174.

Klein-Nulend, J., R.G. Bacabac, and M.G. Mullender, Mechanobiology of bone
tissue. Pathologie biologie, 2005. 53(10): p. 576-580.

175.

Huang, C. and R. Ogawa, Mechanotransduction in bone repair and regeneration.
The FASEB Journal. 24(10): p. 3625-3632.

176.

McCoy, R.J. and F.J. O'Brien, Influence of shear stress in perfusion bioreactor
cultures for the development of three-dimensional bone tissue constructs: a
review. Tissue Engineering Part B: Reviews. 16(6): p. 587-601.

177.

Hoffman, B.D. and J.C. Crocker, Cell mechanics: dissecting the physical
responses of cells to force. Annual review of biomedical engineering, 2009. 11: p.
259-288.
101

178.

Salter, E., et al., Bone tissue engineering bioreactors: a role in the clinic? Tissue
Engineering Part B: Reviews. 18(1): p. 62-75.

179.

de Peppo, G.M., et al., Human progenitor cells for bone engineering applications.
Current molecular medicine. 13(5): p. 723-734.

180.

Skedros, J.G., et al., Analysis of the effect of osteon diameter on the potential
relationship of osteocyte lacuna density and osteon wall thickness. The
Anatomical Record. 294(9): p. 1472-1485.

181.

Ross, M.H. and W. Pawlina, Histology. 2006: Lippincott Williams & Wilkins.

182.

Barati, D., et al., Spatiotemporal release of BMP-2 and VEGF enhances
osteogenic and vasculogenic differentiation of human mesenchymal stem cells
and endothelial colony-forming cells co-encapsulated in a patterned hydrogel.
Journal of Controlled Release. 223: p. 126-136.

183.

Barati, D., et al., Effect of Organic Acids on Calcium Phosphate Nucleation and
Osteogenic Differentiation of Human Mesenchymal Stem Cells on Peptide
Functionalized Nanofibers. Langmuir. 31(18): p. 5130-5140.

102

APPENDIX A
COPYRIGHT RELEASE
Chapter 2

103

Chapter 4

104

